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ABSTRACT OF DISSERTATION 
 
 
 
 
NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS ARE ANTI-
INFLAMMATORY AND TARGET DRY AGE-RELATED MACULAR 
DEGENERATION 
 
Inflammation driven by the NLRP3 inflammasome induces retinal pigment 
epithelium (RPE) cell death in dry age-related macular degeneration (AMD), a 
devastating and currently untreatable blindness that affects tens of millions of 
people worldwide. In the dry AMD model based on Alu RNA accumulation in the 
RPE, cytotoxic non-coding Alu RNAs cause macular degeneration. Although the 
precise molecular details of how Alu RNAs induce inflammasome activation are 
not fully understood, it is known that Alu RNA requires endogenous reverse 
transcriptase (LINE-1) for its life cycle. Therefore, we hypothesized that 
nucleoside reverse transcriptase inhibitors (NRTIs) block inflammasome 
activation and RPE cell death in cell culture and animal models of dry AMD. 
Here, we have identified a novel anti-inflammatory action of NRTIs characterized 
by P2X7 and NLRP3 inflammasome inhibition, and demonstrated their in vivo 
ability to prevent RPE cell death in a mouse model of dry AMD. The tested NRTI 
compounds have been FDA-approved and widely used clinically for decades, and 
are therefore ideal drug repurposing candidates in an unanticipated treatment 
strategy for dry AMD. 
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Chapter 1: Introduction 
1.1 General Background 
Sections 1.1.1 through 1.4 are copied in part, and adapted, from my pre-published 
work 1.  
1.1.1 Age-related macular degeneration 
 
 Age-related macular degeneration (AMD) is a principal cause of blindness in the 
United States and other industrialized nations. An estimated 10 million Americans are 
afflicted with AMD 2, which is comparable in scope to the 12 million living with cancer 
3, or the 5 million with Alzheimer’s disease 4. The prevalence of AMD steadily increases 
with age, affecting 2% of the population at age 40, and one in four people by age 80 2. 
For reasons that are not fully understood, AMD is more common in lightly-pigmented 
and female populations 2. Treatment of AMD is largely an unmet need: There are no 
FDA approved therapies except for a small percentage of individuals with end-stage 
disease.  
There are two types of AMD, the “dry” and “wet” forms. Dry AMD is a chronic 
disease that usually causes some degree of visual impairment, and sometimes progresses 
to severe blindness. In contrast, wet AMD affects only 10-15% of AMD patients, 
emerges abruptly, and rapidly progresses to blindness if left untreated 5,6. Since AMD 
patients typically develop the dry form first, wet AMD occurs on a background of dry 
AMD; as such, dry AMD can be considered a risk factor or even precursor state for wet 
AMD.  
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In the early stages of AMD, which is asymptomatic, insoluble extracellular 
aggregates called drusen accumulate in the retina (See Fig. 1 in 7). The late stage of dry 
AMD, which is also known as geographic atrophy (GA), is characterized by scattered or 
confluent areas of degeneration of retinal pigment epithelium (RPE) cells and the 
overlying light-sensing retinal photoreceptors, which rely on the RPE for trophic support. 
The other late stage form of AMD, the wet form, is typified by choroidal 
neovascularization (CNV) wherein newly immature blood vessels grow towards the outer 
retina from the underlying choroid. These immature blood vessels leak fluid below or 
within the retina.  
It is convenient to dichotomize the pathology of “wet” and “dry” forms of the 
disease based on the presence or absence, respectively, of CNV. However, as an 
understanding of AMD pathogenesis improves, emerging evidence indicates that 
significant overlap exists in the underlying mechanisms of these seemingly disparate 
clinical conditions. In spite of this apparent overlapping pathophysiology, the two forms 
of AMD are indeed somewhat clinically distinct: that is, effective treatment of wet AMD 
does not typically ameliorate the dry AMD component. Clearly, further clarification of 
the overlapping and unique processes that lead to wet and dry pathology will be essential 
for future advances in the prevention and treatment of AMD.  
1.2 The Retina 
1.2.1 In health 
 
For a review of structural features in the healthy retina vs. the AMD-afflicted 
retina, the reader is referred to excellent reviews elsewhere 7,8. The features of a healthy 
ocular fundus is shown in Fig. 1.1 A. Relative to the surrounding peripheral retina, the 
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macular region has a high density of photoreceptors. As such, the macula subserves 
central vision and acuity that enables resolution of fine details, such as edges or borders. 
The retina consists of multiple cell layers that form an interdependent anatomical and 
metabolic network. Other notable features of the retina include: the selectively permeable 
blood-retinal barrier 9, the greatest oxygen consumption per weight of any organ in the 
body 10, and immune privilege 11.  
1.2.2 In AMD 
1.2.2.1 Geographic atrophy 
 
A representative eye with GA is shown in Fig. 1.1 B. AMD primarily affects the 
macular region of the retina, with relative sparing of the surrounding peripheral retina. 
AMD is defined by confluent regions of drusen, which are multi-component, 
heterogeneous aggregates that lie both external and internal to the RPE cells 12,13 (Fig. 
1.2). The emergence and “growth” of drusen occurs slowly over years or decades. RPE 
cell death and synaptic dysfunction accompany underlying drusen 14, although the cause-
effect relationship of drusen and retinal degeneration (which may be reciprocal) is not 
fully understood.  
1.2.2.2 Choroidal neovascularization 
 
 A representative eye with CNV is shown in Fig. 1.1 C. CNV also primarily 
affects the macula. If left untreated, it can lead to severe blindness with scarring within 
several months. Assessment of CNV is typically made using fluorescein angiography or 
optical coherence tomography to measure characteristic lesions with leakage of blood or 
plasma proteins from immature choroidal blood vessels.  
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Figure 1.1 Fundus photographs in health and in AMD 
(A) The ocular fundus of a healthy eye, showing normal pigmentation and retinal blood 
vessels. (B) The late-stage dry form of AMD, known as geographic atrophy. Note large 
regions of depigmentation, especially in the macular, which is at the center of the image. 
(C) In wet AMD, leaky blood vessels from the choroid invade the overlying retina. 
Images are from my previous publication1.  
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Figure 1.2 Toxic accumulations in dry AMD 
Dry AMD is characterized by the accumulation of various types of retinal debris. Image 
adapted from my previous publication1.   
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1.3 The RPE: At the core of AMD pathogenesis 
 
Whereas the step-wise development of certain maladies (e.g. cancers) is relatively 
well-defined 15, no such hallmarks of disease progression have been identified in AMD. 
Nonetheless, the literature abounds with various implicated causes of disease. For want of 
a comprehensive systems approach, one could navigate the numerous avenues and 
permutations by which an ever-growing list of mechanisms contribute to AMD 
pathology. Indeed, such an approach has been emphasized in previous reviews 7,8,16-18. 
Previously, we published an integrated perspective on the mechanisms underlying AMD 
1.  
In general, although inter-individual heterogeneity exists, RPE dysfunction and 
atrophy precedes the latter stages of AMD (GA or CNV). As such, most model systems 
in AMD focus on the RPE as the fulcrum of AMD pathogenesis. The RPE integrates 
numerous stimuli to define its own health, while also receiving and broadcasting signals 
to and from the retinal microenvironment. The capacity of the RPE to modulate diverse 
pathways of AMD pathogenesis can be gleaned from RNA transcriptome analyses of 
human AMD donor eyes 19,20 and in vitro RPE cells 21. Genome-wide stress-response 
transcriptome and proteome assays have begun to catalog the effect of specific AMD-
associated stresses 22, and age-related changes in retinal molecular composition 23,24 on 
whole-genome RPE gene expression. Although the vitality of the RPE cell is paramount 
to retinal health, it is also true that perturbations in other tissues, for example, the 
choroid, Bruch’s membrane and photoreceptors, are important burdens on the retinal 
microenvironment. Nevertheless, the critical event in AMD pathogenesis, from which 
there is no return, is RPE dysfunction and degeneration.  
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1.4 Dicer/Alu RNA model of geographic atrophy (GA) 
 
Our laboratory pioneered a mouse model of geographic atrophy (GA) based on 
the accumulation of toxic non-coding RNAs called Alu RNAs in the RPE. We found that 
DICER1, a ribonuclease, was specifically reduced in the RPE of late stage dry AMD 
(GA) patients 25; moreover, this pathological decrease in DICER1 was accompanied by 
the aberrant overabundance of the non-coding Alu RNA, which is toxic to RPE cells.  In 
that study, we presented several experimental approaches to model GA in mice: the 
genetic ablation or knockdown of DICER1 in the mouse RPE, or, as will be utilized in 
this dissertation, the administration of synthetic Alu RNAs.   
The Alu RNAs that accumulate in DICER1 deficiency are transcribed from Alu 
DNA sequences in the nuclear genome. Sometimes described as “genomic parasites”, 
these ~300 nt DNA sequences constitute at least 11% of all genomic DNA 26. Alus are 
retrotransposons, meaning they “jump” around the genome by 1) Transcription; 2) 
Reverse transcription; and 3) Genomic integration at a new locus. The deleterious effect 
of Alu sequences is often ascribed to a single retrotransposition event; for example, an 
Alu sequence may insert into a critical gene, thereby disrupting gene function 27. The 
relevance of reverse transcription to the Alu-induced model of GA will be tested in part 
and discussed throughout this dissertation.   
1.4.1 NLRP3 inflammasome in GA 
 
Recent work from our group has identified an innate immune complex called the 
NLRP3 inflammasome as the response platform that mediates Alu RNA-induced RPE 
cell death 28. The NLRP3 inflammasome is a complex of three proteins (NLRP3, ASC, 
Caspase-1) that is best known for its role in maturing bioactive interleukin-1 beta and -
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18, which allows for their release from cells (Fig. 1.3) 29. In our study we provided 
evidence of inflammasome activation in the RPE of human GA donor eyes, and showed 
that in experimental DICER1 deficit, activation of the NLRP3 inflammasome by Alu 
RNA leads to RPE IL-18 secretion, which induces MyD88-dependent RPE cell death. 
This finding helps solidify the central role of the RPE in AMD pathogenesis. 
Interestingly, to date, NLRP3 inflammasome activation is almost exclusively confined to 
immune cells, thereby presenting an identity crisis for the RPE, which can now be re-
defined, in part, in terms of its immune function. As will be discussed in section 2.4.1, the 
NLRP3 inflammasome appears to be a convergent integrator of multiple AMD-related 
stressors (not just Alu RNAs).  
1.4.2 Unresolved mechanisms of Alu toxicity 
 
The mechanism of Alu RNA-induced toxicity is depicted in Fig. 1.3 (adapted 
from 28) and is based on the findings from three works of our laboratory 28,30,31. The most 
upstream molecular player involved in Alu-induced inflammasome activation is the cell-
surface ATP receptor P2X7. However, the molecular details that connect Alu RNA 
overabundance to P2X7 activation remain unclear.  
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Figure 1.3 Mechanism of Alu-induced RPE cell death  
 
Alu RNA activates P2X7 to induce mitochondrial reactive oxygen species-mediated 
priming (increased transcription) of NLRP3 and interleukin mRNAs. Alu RNA also 
induces formation of the inflammasome complex, which processes interleukins to their 
mature form. Alu-induces RPE cell death via MyD88 and phosphorylation of IRAK1/4.  
Adapted from 28. 
 
1.5 Scope of thesis  
The best-known function of cytotoxic Alu RNAs is invasion of and replication 
within the genome. In this natural life cycle of Alu RNAs, genomic Alu sequences are 
transcribed into Alu RNA, and the Alu RNA is copied and inserted back into the genome 
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via a reverse transcriptase-dependent mechanism (Fig. 2.1). We hypothesized that the life 
cycle of Alu RNA is an important mechanistic step that links its accumulation to RPE cell 
death and inflammation, and that interference with the Alu life cycle using reverse 
transcriptase inhibitors would block these Alu-induced effects. Thus we set out to test 
whether nucleoside (analog) reverse transcriptase inhibitors (NRTIs) are protective in the 
Alu-induced model of AMD, and also, more broadly, whether these compounds are 
inhibitors of the NLRP3 inflammasome and P2X7 in other non-Alu-based experimental 
systems. As will be shown, our hypothesis that the Alu RNA life cycle is connected to 
RPE death was not correct: Even though NRTIs were protective and blocked RPE cell 
death when treated with Alu RNA, our investigation into the mechanism of their 
protective effect revealed that NRTIs possess an intrinsic NLRP3 inflammasome-
inhibitory effect that did not require their phosphorylation. Since NRTI phosphorylation 
is required in order for their function as reverse transcriptase inhibitors, our findings 
indicate that the inflammasome-inhibitory effect we observed occurs independently of 
reverse transcriptase inhibition. Using one NRTI (d4T; stavudine) to explore the 
mechanism of this intrinsic anti-inflammatory effect, we showed that d4T selectively 
antagonized P2X7 function and was remarkably protective in other P2X7-dependent cell 
culture and animal models that are not known to signal via reverse transcriptase.   
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Chapter 2 Nucleoside reverse transcriptase inhibitors block Alu-induced RPE 
degeneration and NLRP3 inflammasome activation 
 
2.1 Introduction 
 
 Degeneration of the RPE is hallmark of dry AMD, and is thought to be an inciting 
event in the disease pathogenesis. The NLRP3 inflammasome is a common integrator of 
multiple AMD-related stressors (see discussion 2.4.1), and an essential mediator of Alu-
induced RPE toxicity.  
 Like Alu RNA, HIV is another pathogen that activates the NLRP3 inflammasome 
(see discussion 3.4.5). We noticed a similarity between Alu RNAs and HIV: their life 
cycles both require reverse transcriptase (Fig. 2.1). Although it is clear that inhibition of 
the viral life cycle with nucleoside reverse transcriptase inhibitors (NRTIs) is part of a 
functionally curative treatment regimen in the case of HIV, it is not known whether 
NRTIs inhibit Alu-induced NLRP3 activation or RPE degeneration.  
 As such, the present studies were designed to investigate whether NRTIs prevent 
RPE degeneration induced by Alu RNA. We will test the hypothesis that NRTIs inhibit 
the NLRP3 inflammasome, which in turn dampens the signaling pathways that drive RPE 
degeneration.  
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Figure 2.1 Reverse transcriptase-dependent replication of Alu RNA and HIV RNA.  
 
Alu and HIV RNAs are genomic parasites. The life cycle of each RNA involves 
transcription from the host genome into an RNA intermediate, followed by reverse 
transcription and re-integration as a copy elsewhere in the genome.  
 
 
 
2.2 Materials and Methods 
 
 
2.2.1 Cell culture  
 
Primary human RPE cells were isolated and purified from fetal retina (gift from 
D. Hinton, University of Southern California). Primary mouse RPE cells were isolated 
from C57/Bl6J mice. Cells were used for experiments between passages of 4 and 7, with 
routine split of cells at 1:3 with each passage.   
RPE cells were cultured in high-glucose DMEM with 10% (human) or 20% 
(mouse) fetal bovine serum (FBS) supplemented with 2 mM L-Glutamine and 100 U/mL 
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Penicillin/Streptomycin (P/S). Transfection of Alu RNA was performed using 
Lipofectamine 2000 (Invitrogen), according to the manufacturer’s instructions. For 
transfection in 6 well dishes, RPE cells were transfected with 1.5 mL of plating media 
(DMEM 10 or 20%, as above, except without P/S) and 500 µL of transfection mix in 
Opti-MEM (Invitrogen). For a 6 well dish, the transfection mix consisted of 10 µg 
(approximately 100 pmol) of in vitro transcribed Alu RNA (see below) and 5 µL 
Lipofectamine 2000. Cells were transfected at approximately 70 % confluency, and 
media was replaced with 10% DMEM (+ P/S), with inhibitors, eight hours after 
transfection. Protein for western blot was collected at 24-30 hours after transfection (see 
below).     
NRTIs (d4T (stavudine), 3TC (lamivudine), AZT (zidovudine), ABC (abacavir)) 
were obtained from Sigma-Aldrich. NRTI powders were reconstituted in UltraPure water 
(Invitrogen) and added to cell culture media at a final concentration of 25-100 µM (for 2 
mL final volume) 20 minutes before transfection mix was added to cells.       
 In vitro transcribed RNA was synthesized using the AmpliScribe-T7 High Yield 
Transcription Kit (Epibio) from a DraI-linearized plasmid containing an AluY sequence 
with upstream T7 promoter sequence (see Appendix for plasmid information; plasmid 
gift of James A. Goodrich, University of Colorado).   
2.2.2 Western blot  
 
Protein samples were run on 4-20% or 4-12% tris-glycine SDS-PAGE gels, 
transferred to PVDF membrane (0.2 or 0.45 µm), and blotted with antibodies against 
Caspase-1 (1:500, Invitrogen); pIRAK4 (1:500, Cell Signaling); Vinculin (1:1,000, 
Sigma-Aldrich). Cells were homogenized in RIPA buffer (Sigma) with protease and 
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phosphatase inhibitors (Roche) or lysed directly in 1x Laemmli buffer (4x recipe: 8% 
SDS; 20% 2Mercapto-ethanol; 40% glycerol; 0.04% bromophenol blue; 0.25 M Tris-HCl 
pH 6.8). For RIPA extraction, protein concentrations were determined using a Bradford 
assay kit (Bio-Rad) with bovine serum albumin as a standard. Primary antibody 
incubation was performed overnight at 4 °C. Protein loading was assessed by 
immunoblotting using an anti-vinculin antibody. Secondary antibodies (Santa Cruz, 
1:5000; or LICOR, 680/800 nm IRdyes, 1:20000) were used for 1 hour at room 
temperature. The signal was visualized using a luminol detection kit (Santa Cruz) and 
captured on UltraCruz ultraradiography film (Santa Cruz) or using the LICOR Odyssey 
Imager.  
2.2.3 Mice 
 
Ocular animal experiments were in accordance with the Association for Research 
in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and 
Visual Research. All experiments were performed on wild-type male C57BL6/J mice age 
6-8 weeks, purchased from The Jackson Laboratory. Mice were habituated for at least 72 
hours in the Division of Laboratory Animal Resources upon arrival to the University of 
Kentucky and housed in plastic cages (bedding and enrichment) with cage mates and ad 
libitum access to food and water and maintained on a 14:10 hour light:dark light cycle. 
For all procedures, anesthesia was achieved by intraperitoneal injection of 100 mg/kg 
ketamine hydrochloride (Ft. Dodge Animal Health) and 10 mg/kg xylazine (Phoenix 
Scientific), and pupils were dilated with topical 1% tropicamide (Alcon Laboratories).  
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2.2.4 Alu-induced model of RPE degeneration and drug administration in 
mice  
Subretinal injections (SRI) (1 µL) in mice were performed using an Ito 
microsyringe (Ito Corporation). In vivo transfection of plasmids coding for an Alu 
sequence (pAlu) or empty control vector (pNull) was achieved using 10% Neuroporter 
(Genlantis) as described previously 31. For oral administration, d4T was mixed with 
carboxymethylcellulose (CMC) sodium salt (Sigma) (final concentration of CMC was 
0.5%) delivered once daily by oral gavage at 150 mg/kg, or twice daily (every 12 hours) 
by oral gavage at 50 mg/kg (total 100 mg/kg/day). CMC alone was used as vehicle 
control. For intraperitoneal injection of AZT, AZT was dissolved in UPS-grade 1x PBS 
(Gibco) was administered twice daily (50 mg/kg/administration) for (vs. control PBS). 
For both oral gavage and intraperitoneal administration, NRTIs (or control) were 
delivered daily, starting in the evening one day before morning-time SRI, and lasting 
until six days after SRI, at which time the experimental timeline concluded. Technical 
assistance with animal procedures was provided by Younghee Kim (Ambati Lab).  
2.2.5 Fundus photography  
   
Fundus imaging of dilated mouse eyes (see section 2.2.3 Mice) was performed on 
a TRC-50 IX camera (Topcon) linked to a digital imaging system (Sony).   
2.2.6 RPE flat mount, ZO-1 staining and confocal imaging 
 
Briefly, mouse RPE/choroid flat mounts were fixed with 4% paraformaldehyde or 
100% methanol, stained with antibodies against zonula occludens-1 (ZO-1) and 
visualized with Alexa594 (Invitrogen). All images were obtained using the Leica SP-5 
microscope. Detailed protocol is as follows:  
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1.  After fundus photograph, euthanize mouse and remove entire eyeball with forceps 
(grabbing the optic nerve). 
2.  Slit the cornea and remove cornea, lens, and neural retina tissues, leaving behind the 
retinal pigment epithelium/choroid complex (RPE/C).  
3.  Fix the RPE/C and Sclera in 2% paraformaldehyde/1x PBS for 30 min at 4° C, with 
gentle shaking. 
4.  Wash in 1x PBS for 5 min (× 2) at 4°C. 
5.  Wash in 10 mM TBS for 5 min (× 2) at 4°C. 
6.  Permeabilize in 10 mM TBS-T (containing 0.2% Triton X-100) for 20 min at 4°C, 
with gentle shaking. 
7.  Incubate in Blocking Buffer (3% BSA + 2% NGS/TBS-T) for 2-4 h at 4°C. 
8.  Incubate in primary antibody (rabbit ZO-1; Invitrogen #61-7300)(1:50 in Blocking 
Buffer) overnight (~>16 h) at 4°C. 
9.  Wash in 10 mM TBS-T for 5 min (× 3) at 4°C. Protect samples from light for all 
following steps.  
10. Incubate in secondary antibody (AF594 goat anti-rabbit IgG, 1:500 in Blocking 
Buffer) for 2 h at 4°C. 
11. Wash in 10 mM TBS-T for 5 min (× 3) → 10 mM TBS for 10 min (× 1) at 4°C.   
12. Cut radially and wet-mount the RPE flats using Vectasheld (≈ 55 ul/flat). 
13. Photography using the AOBS SP5 confocal microscope in BBSRB confocal suite. 
Settings: * HyD488/594 (Offset: 0):  Laser power (A594): 30% - Gain: 30% - Pinhole: 
100%.   
2.2.7 Northern blot 
 
Total RNA from biotin-UTP Alu RNA-transfected cells was extracted using 
Trizol reagent (Invitrogen) according to the manufacturer’s instructions. RNA samples 
were run on 10% TBE-urea gels (Biorad) at 150 V in 1x Tris-Borate-EDTA (TBE) 
running buffer. Samples were transferred from the gel to a HyBond N+ nylon membrane 
(GE) using a wet transfer method (0.5x TBE transfer buffer; 1 hr at 75 V; on ice; 
transfers can also be performed overnight in cold room (4 °C) at 30 V). After briefly 
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drying at room temperature (about five minutes), the membrane was UV cross-linked 
(240 mJ/cm2). Membrane was blocked in pre-hybridization buffer (Recipe: 10 mL 
deionized formamide, 5 mL NaH2P04 pH 7.2, 1 mL NaCl 5M, 160 uL EDTA 250 mM, 3 
mL h20, add 1.4 g SDS; denatured herring sperm DNA, 300 µL (100 °C, 5 min). 
Membrane blocked at 42 °C for at least 30 minutes before addition of probe. Membrane 
was blotted for u6 RNA loading control using a biotinylated oligonucleotide probe 
synthesized by IDT (5’ CACGAATTTGCGTGTCATCCTT-Biotin 3’), with 
hybridization at 42 °C overnight in a glass tube rotating in a rotisserie hybridization oven. 
After overnight hybridization, membranes were washed in 2xSSC, 0.1% SDS, twice, for 
15 minutes each wash, at 42 °C, and then developed with the Thermo Pierce 
chemilluminescent nucleic acid detection kit according to the manufacturer’s instructions, 
and captured on UltraCruz ultraradiography film (Santa Cruz).  
2.2.8 Densitometry 
 
Densitometry for western and northern blots was performed using ImageJ 
software and according to the instructions included therein 32.  For each experiment, all 
blots of biological replicates (“n”) were analyzed independently and normalized to 
housekeeping gene (vinculin). Mean values of experiments are presented in 
representative images.    
2.2.9 Fisher’s exact test for fundus photograph analysis 
 
Fisher’s exact test (two-tailed) was performed for fundus photographs using 
GraphPad software. Fundus photographs were de-identified and graded as “yes” or “no” 
in terms of induction or prevention of RPE degeneration, respectively. Typical induction 
of RPE degeneration by Alu was about 25% of the visible area of the fundus photograph.    
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2.3 Rationale and Results 
 
 
2.3.1 NRTIs inhibit Alu-induced NLRP3 inflammasome activation 
 
Since Alu and HIV both rely on reverse transcriptase for their life cycle, we 
hypothesized that NRTIs block Alu RNA-induced cytotoxicity. Alu RNA mediates RPE 
cell death via activation of Caspase 1 and the NLRP3 inflammasome 28,30. The NRTI 
stavudine (d4T; 2’3’ dideoxythymidine; Zerit, Bristol-Myers Squibb), which is FDA-
approved for the treatment of HIV infection, prevented Caspase 1 cleavage to its active 
(p20) form 33,34 in primary human (Fig. 2.2 a) and wild-type mouse RPE cells (Fig. 2.3 a). 
Importantly, d4T did not reduce Alu RNA levels (Fig. 2.3 b), as determined by northern 
blot of human RPE cells transfected with biotin-UTP body-labeled Alu RNA with or 
without d4T treatment (for detailed methods see Section 2.2.7). Several time points were 
analyzed (1, 4 and 24 hours), which span the course of typical in vitro experiments to 
analyze Alu-induced molecular effects (e.g. Caspase-1 cleavage at 24 hrs; peak ATP 
release from cells at 4-6 hours). This result indicates that d4T prevents Alu-induced 
Caspase-1 activation downstream of Alu RNA accumulation (i.e. it does not simply 
prevent Caspase-1 activation by modulating Alu RNA levels). As such, we next sought to 
determine whether d4T blocked other molecular hallmarks of the model established in 
previous work and depicted in Figure 1.3.   
Indeed, d4T also blocked phosphorylation of IRAK4, a kinase downstream of the 
MyD88 adaptor that mediates Alu RNA-induced RPE cell death 28, in primary human and 
wild-type mouse RPE cells (Fig. 2.2 a and Fig. 2.3 a). Other NRTIs, including the anti-
HIV drugs azidothymidine (AZT; 3'-azido-2',3'-dideoxythymidine; Retrovir, ViiV 
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Healthcare), lamivudine (3TC; 2’3’ dideoxycytidine; Zeffix, GlaxoSmithKline) and 
abacavir (ABC; a di-deoxyguanosine analog; Ziagen, ViiV Healthcare), also blocked 
Caspase-1 cleavage induced by Alu RNA (Fig. Fig. 2.2 b). 
 
2.3.2 NRTIs inhibit Alu-induced RPE degeneration in mice 
 
NRTIs are typically administered orally to HIV patients, in pairs, at a total NRTI 
dose of up to 15 mg/kg/day (equivalent dose in mice: 185 mg/kg/day). Twice daily 
administration of oral d4T (every day throughout the course of the experiment; see 
Section 2.2.4) at a clinically relevant dose (100 mg/kg/day) in wild type mice prevented 
Alu-induced RPE degeneration 28,31 (Fig. 2.2 c; p = 0.0003; n = 12). 9 of 12 eyes from 
d4T-treated mice were protected from RPE degeneration, whereas all 12 eyes from 
vehicle-treated mice exhibited RPE degeneration. Also, a single administration of oral 
d4T at 150 mg/kg/day (again, daily throughout the course of the experiment) prevented 
Alu-induced RPE degeneration (p = 0.015, n = 6 per group), with 5 out of 6 eyes from 
d4T-treated mice protected from Alu-induced RPE degeneration, and all 6 eyes from 
vehicle-treated mice exhibiting degeneration. Finally, Alu-induced RPE degeneration in 
wild type mice was also blocked by twice daily intraperitoneal administration of 50 
mg/kg AZT (daily throughout the course of the experiment). 
 
	  
	   20	  
	  
	   21	  
Figure 2.2 NRTIs block Alu-induced RPE degeneration and Caspase-1 activation 
  
(A) Western blot of Caspase-1 activation (p20 subunit) and IRAK4 phosphorylation in 
primary human RPE cells transfected with Alu RNA + d4T (100 µM).   
(B) Western blot of Caspase-1 activation in human RPE cells transfected with Alu RNA 
+ NRTIs (3TC, AZT, ABC) (100 µM).  
(C-D) Fundus photographs (top row) and flat mounts stained for zonula occludens-1 (ZO-
1; red) (bottom row) show that (C) twice daily oral administration of d4T (50 mg/kg; 
total 100 mg/kg/day) and (D) twice daily intraperitoneal administration of AZT (50 
mg/kg; total 100 mg/kg/day) prevented RPE degeneration induced by a plasmid 
expressing Alu RNA. In fundus photographs degeneration outlined by blue arrowheads. 
Scale bars, 50 µm. See also Figure 2.3.  Images representative of n = 3-4 (a,b), n = 8-12 
(c,d). Fisher’s exact test p-value of (c) pAlu + vehicle vs. pAlu + d4T: 0.0003; (d) pAluA 
+ vehicle vs. pAlu + AZT: 0.0004.    
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Figure 2.3 d4T blocks Caspase-1 activation without reducing Alu RNA levels.  
 
(A) Western blot of Caspase-1 activation (p20 subunit) and IRAK4 phosphorylation in 
primary mouse RPE cells transfected with Alu RNA + d4T (100 µM). Image 
representative of n = 4.  
(B) Northern blot of biotin-UTP-labeled Alu RNA-transfected primary human RPE cells. 
D4T (100 µM) did not reduce Alu RNA levels (normalized to u6 RNA). Alu RNA-
transfected cells in culture assayed at 24 hours for western blotting (Fig. 2.2 a-b, Fig. 2.3 
a).    
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2.4 Discussion 
 
2.4.1 Drug repurposing of NRTIs for dry AMD 
 
There are no effective therapies for dry AMD; therefore, our finding that NRTIs 
are effective in a mouse model of disease are of great importance in terms of their 
potential as therapeutics. The use of NRTIs to fill this niche is particularly appealing 
given the advantages of repurposing FDA-approved drugs. Drug repurposing surmounts 
major obstacles of traditional drug development of novel compounds; importantly, the 
costs of development are greatly reduced; the time from clinical investigation to FDA-
approval is minimized; safety risks are limited because the toxicity profile and 
pharmacokinetics of these compounds has already been extensively demonstrated 35,36. 
Drug repurposing of NRTIs should also be a boon for patients as these drugs are off 
patent and predictably inexpensive.  
The translatable potential of NRTIs would be bolstered by future investigations 
showing their protective effect in other models of dry AMD. We predict that NRTIs will 
be similarly effective in other models of dry AMD, which are also driven by the NLRP3 
inflammasome. Based on the concordance of these models with human data, it is 
increasingly apparent that the NLRP3 inflammasome is a convergent integrator of 
multiple AMD-associated molecular stressors (e.g. Alu RNA 28; lysosomal destabilization 
37; oxidative stress 38; A2E 39; beta-amyloid and complement 40,41.  
If nucleoside analogs are to be explored as potential therapeutic agents in humans, 
it will also be important to consider that patients with dry AMD are at greatly increased 
risk of also developing CNV 1. Future work could determine whether NRTIs affect CNV 
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in mice. Data in press from our laboratory indicate that inflammasome inhibition does not 
affect CNV, although other studies suggest that the inflammasome might modulate CNV 
42,43. Regardless of whether the NLRP3 inflammasome drives CNV, it will be important 
to directly test any putative therapeutic agent for the treatment of dry AMD in terms of its 
effect on CNV.  
2.4.2 Translational considerations: Dosing and route of administration 
 
 NRTIs are typically administered as oral pills in adult humans. This method of 
delivery is convenient and well understood from a pharmacokinetic and adverse effect 
standpoint. We recapitulated oral administration in our mouse model of dry AMD, 
showing that oral d4T blocked Alu-induced RPE degeneration. The dose that optimally 
blocked RPE cell death was twice daily administration of 50 mg/kg d4T (total 100 
mg/kg/day), which is the biological equivalent of about 8 mg/kg/day in humans, based on 
body weight and surface area conversion 44. The dose used in our experiment is therefore 
about four times as high as the amount of d4T administered in humans (~ 2 mg/kg/day). 
However, a typical adult human regimen for HIV therapy includes a pair of NRTIs (e.g. 
40 mg d4T and 400 mg didanosine; 150 mg lamivudine (3TC) and 300 mg zidovudine 
(AZT)), twice a day 45-47. Therefore, the total dose of NRTI delivered in our experiments 
was considerably lower compared to human equivalent doses. For example, the NRTI 
load of monotherapy AZT for a 60 kg human would be 10 mg/kg/day, or the equivalent 
of 123 mg/kg/day in mice, whereas we prevented RPE degeneration at a dosing regimen 
of 100 mg/kg/day of AZT in our Alu-induced model. Importantly, the therapeutic doses 
required in humans would be expected to be dramatically even lower considering the 
acute, powerful nature of Alu stimulus in mice compared to a more insidious 
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development of RPE disease (progressing on the time scale of years to decades) in the 
human condition.    
This rationale suggests that many of the side effects attributed to NRTI use (e.g. 
bone marrow suppression; peripheral neuropathy; lipodystrophy)48 could be avoided, or 
at least greatly reduced, in AMD therapy. For example, in AZT monotherapy trials, 
unlike high doses of AZT (1500 mg/day) low doses (500 mg/day, which is three times 
higher than the equivalent surface area-body weight conversion in mice) did not produce 
hallmark adverse effects of neutropenia and anemia compared to placebo after a mean 
follow-up of 55 weeks. In fact, nausea was the only adverse effect with significant 
increase in patients taking low-dose AZT compared to placebo 49. The side effects 
experienced with d4T use (e.g. peripheral neuropathy) are also well characterized in 
terms of dose-dependence 50, which would facilitate dose optimization to avoid adverse 
events in AMD patients taking NRTIs.        
Another approach to avoiding adverse effects associated with high doses of a 
single NRTI would be to combine NRTIs into a single formulation; since multiple NRTIs 
appear to have similar protective effects in vitro and in vivo for the Alu-induced model of 
GA, yet different toxicity profiles, one could imagine that a formula combining low doses 
of multiple NRTIs might be as effective at blocking RPE degeneration as a large dose of 
a single NRTI (this could be explored in future experiments).  
Yet another drug delivery option would be intraocular administration. An 
important issue to be further elucidated is whether the effect of NRTIs is a direct effect in 
the eye. In preliminary experiments we noted that ocular delivery (intravitreous injection) 
of d4T prevented RPE degeneration in the Alu-induced model. Consistent with the idea 
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that d4T and NRTIs can act locally on the RPE, the data presented herein (Fig. 2.2) 
indicate that d4T can produce a direct effect on RPE cells in culture. If NRTIs act locally 
in the eye, then systemic administration of NRTIs, which have a short half-life (20-30 
minutes in mice; 60-120 minutes in humans) 51,52, is probably an inefficient mode of 
delivery to the site of RPE cell death 53. Future work could determine the efficacy of 
topical (e.g. eyedrops) 54 or intravitreous delivery of NRTIs in the Alu and other models 
of dry AMD.   
 
2.4.3 NRTI-induced cell dysfunction  
 
Although NRTI use has been associated with various cell toxicities, including 
reduced viability, mitochondrial function and proliferation, and increased lactate 
production 55-57, RPE cells exposed to NRTIs up to 100 µM do not exhibit a reduction in 
cell viability or cell death (at one week in mice; 48-72 hrs in cell culture) (unpublished 
observations monitored by ZO-1 flatmount/fundus imaging (in vivo) and MTS assay (in 
vitro)). NRTI-induced dysfunction of non-RPE cells is attributed primarily to mtDNA 
defects; perhaps RPE cells are resistant to NRTI-induced dysfunction because of their 
great metabolic capacity in vivo (highest metabolic rate per weight of tissue 10, and as 
such they have a large buffer capacity. Furthermore, it is known that the kinases 
responsible for phosphorylating certain pyrimidine NRTIs (e.g. AZT) are elevated during 
mitosis 58; post-mitotic (in vivo) or slowly dividing (in vitro) RPE cells may be resistant 
to NRTI-induced toxicity due to low expression of such kinases, an issue that could be 
addressed in future work.   
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2.4.4 Risk of AMD in humans taking NRTIs 
 
  A potential corollary to the presented findings would be that HIV patients might 
be at reduced risk of developing AMD because of their chronic exposure to NRTIs. Until 
now, it has not been possible to address this question for several reasons. In order to have 
sufficient power to detect a significant clinical difference, a study population of about 
2,000 controls and HIV patients would be required: The point prevalence of pure GA is 
about 2% in those over 70 and 3% in those over 75 59,60. To have 80% power to detect a 
change in the rate from 2% to 1% in 70 year olds, one would need 2276 participants in 
each group and to detect a change in the rate from 3% to 1.5% in those over 75 one 
would need 1506 participants in each group (correspondence Chelsea E. Myers, M. Stat, 
University of Wisconsin-Madison). However, the number of reported HIV positive 
patients aged 65 and older has been low until just recently (6,580 in 2001 vs. 36,462 in 
2010) 61,62. As such, the logistics of such an analysis are becoming increasingly feasible.  
However, there are several important challenges to an analysis of AMD 
phenotype in HIV patients. For one, such a study will need to take into account the 
number of years and dosing of multiple NRTIs. Also, one would need to consider that 
HIV patients take a number of other anti-viral drugs (e.g. protease inhibitors and non-
nucleoside reverse transcriptase inhibitors), including ritonavir, which is associated with 
RPE abnormalities 63.  
In this respect, patients with chronic hepatitis B virus (HBV; affecting 350 million 
people worldwide) might be a better study population for assessing the effect of NRTIs 
on AMD phenotype. The NRTI lamivudine (3TC) is used long-term in some HBV 
patients (e.g. median treatment duration 90 months; 64) including the elderly (60 years 
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and older; 65). Moreover, in contrast to HIV 66, unmanaged HBV is not known to cause 
retinal abnormalities.  
 Even if HIV/HBV patients are at reduced risk of developing AMD, it will not be 
possible to parse out the effects of virus from NRTI use. Although a population of long-
term NRTI users does not currently exist, it is possible that one will exist in the future.  
The NRTI-containing prophylactic Truvada® was approved in 2012 by the FDA for HIV 
prevention (or “pre-exposure prophylaxis”). If the at-risk-for-HIV patient population 
were to take this NRTI compound for decades, and remain HIV-free, then this would be 
an ideal population to parse the effects of virus from NRTI on AMD. However, such an 
analysis of NRTI use in HIV-free individuals would likely require decades of NRTI 
exposure and is predicated on the efficacy of prophylaxis, and survival of the population 
until a reasonable prevalence of AMD occurs in order to perform a sufficiently powered 
statistical analysis (see discussion earlier in section 2.4.4).   
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Chapter 3: NRTIs block NLRP3 inflammasome activation independent of reverse 
transcriptase inhibition 
3  
 
3.1 Introduction 
3.1.1 Life cycle of Alu RNA 
 
 Human cells contain a variety of active, endogenous reverse transcriptases (RTs), 
including L1 67 and telomerase 68. These enzymes are broadly expressed and functional in 
multiple cell types, in both health and disease 69-73. However, RPE cells do not express 
telomerase 74, and it is not known whether RPE have other sources of endogenous RT 
activity. Nevertheless, given that Alu RNA is a known substrate for RT, and that NRTIs 
block Alu-induced toxicity, it is worth discussing the plausibility that Alu RNA activates 
the NLRP3 inflammasome via RT, and that the protective effect of NRTIs observed in 
Chapter 2 is achieved via their classic RT inhibitor function.  
Reverse transcription of Alu RNA is known to occur in somatic cells in a process 
that requires the host-encoded endogenous RT known as L1 67. In this process, known as 
retrotransposition, RT of Alu RNA by L1 is coupled to insertion of Alu RNA into the 
genome via a target-primed-reverse transcriptase mechanism that involves priming of the 
first strand cDNA by the host chromosome 26,75,76. At present it is clear that insertion of 
an Alu copy into a new chromosomal locus can produce a plethora of genomic 
disruptions, for example: insertional mutagenesis, transduction, and ectopic 
recombination 77. RT inhibition would prevent successful integration events, and 
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therefore much of this genomic instability. As Alu RNAs are increased in the human RPE 
of dry AMD patients, it would be interesting to determine if these patients also have 
increased levels of genomic Alu DNA levels, which could be answered using the “RC–
seq” technique, which involves hybridization of genomic Alu sequences to a microarray 
chip, followed by next-generation sequencing and mapping of novel Alu insertions 
compared to the known reference human genome(s) 69. As RPE cells are typically post-
mitotic, they are optimal system for studying somatic retrotransposition, as Alu insertions 
would be fossilized throughout life.  
 
3.1.2 Arguments against RT-mediated Alu RNA-induced RPE degeneration 
 
The original rationale for this dissertation was based on the similarity in life cycle 
of Alu and HIV RNAs (Fig. 2.1). However, upon a detailed examination of the literature, 
we questioned the likelihood RT inhibition was responsible for the observed anti-
inflammatory effects of NRTIs in the Alu-induced model of AMD. Therefore, in Chapter 
3, we directly test whether the ability of two NRTIs to block RPE degeneration and 
inflammasome activation is mediated by reverse transcriptase inhibition. The following 
considerations led us to question our original rationale.  
In pilot cell culture experiments, we noted that NRTIs blocked inflammasome 
activation by other stimuli, such as lipopolysaccharide/ATP, which are not known to 
signal via reverse transcriptase. Furthermore, partial inhibition of this inflammasome 
activation and RPE cell death by NRTIs was seen at 25 µM, with optimal rescue, 
typically full blockade of Caspase-1 processing to its p35 intermediate active form, or 
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IRAK4 phosphorylation, was seen at doses of 50-100 µM (Fig. 3.1). However, this NRTI 
  
Figure 3.1. d4T blocks LPS/ATP-induced Caspase-1 activation and IRAK4 
phosphorylation in primary human RPE cells. Activation of Caspase-1 seen by 
processing to its intermediate active 35 kDa band. Image representative of n = 2-3 
experiments. 
 
dose is much higher than the IC50 of known endogenous reverse transcriptases, and 
therefore not consistent with the idea that reverse transcriptase mediates Alu-induced 
toxicity. For example, the IC50 of various NRTIs we tested (Fig. 2.2 a-b) for L1-
mediated retrotransposition is in the low micromolar range 78,79 (0.22 to ~ 5 µM). In 
addition, the in vitro transcribed Alu sequence used in our studies lacks a polyA tail; it is 
known that Alu sequences lacking a polyA are not mobilized by L1 80. 
Furthermore, RPE cells do not exhibit telomerase activity 74, but even if they 
expressed a very low amount, the IC50 of telomerase by NRTIs is also not compatible 
with the hypothesis that telomerase mediates the observed effect that NRTIs block 
inflammasome activation in vitro. For example, the IC50 of the triphosphate forms of 
AZT and d4T are 44 and 24 µM, respectively 81. Since only a small fraction (0.5-2%) of 
intracellular AZT and d4T is metabolized by the cell to their triphosphate forms 82, NRTI 
concentrations on the order of hundreds of micromolar or low millimolar would be 
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required to achieve these levels of triphosphate in cells. Indeed, telomere shortening 
induced by AZT is only observed after weeks of culture at 100-800 µM 83,84.    
Alternatively, it is conceivable that NRTIs could function as nucleoside-
triphosphates through inhibition of non-RT enzymes, such as other host DNA 
polymerases. Inhibition of DNA polymerase-gamma by NRTIs (IC50s are much lower 
for -gamma compared to other DNA polymerases) leads to a reduction in mtDNA levels, 
a mechanism that is thought to drive mitochondrial effects of anti-HIV therapy 55,85. Since 
the release of mtDNA from the mitochondrion to cytoplasm is a known trigger for 
NLRP3 activation 86, at first glance mtDNA depletion seems like a plausible mechanism 
by which NRTIs could inhibit inflammasome activation. However, as will be addressed 
in this chapter, inflammasome inhibition in our model is achieved before significant 
reductions in mtDNA are observed. Finally, different NRTIs have dramatically different 
ranges of IC50 for DNA polymerase gamma 85 despite showing a similar effective dose 
in blocking Alu-induced inflammasome activation, suggesting that this pathway is not a 
crucial mediator of the protective effect of NRTIs. Therefore, to test directly whether 
NRTIs are anti-inflammatory via reverse transcriptase inhibition, we utilized two systems 
in which the NRTIs d4T and AZT were not capable of becoming phosphorylated: we 
synthesized a methoxy-substituted variant of d4T, and also tested AZT in a cell line that 
lacks thymidine kinase (the enzyme required for the first phosphorylation step of AZT).  
In these systems, despite this incapacity for phosphorylation, these NRTIs still blocked 
NLRP3 inflammasome activation.     
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3.2 Materials and methods 
3.2.1 Cell culture 
 
Please refer to section 2.2.1. For pilot LPS/ATP experiments in primary human 
RPE (Fig. 3.1), confluent RPE cells were primed for four hours with 1000 ng/mL LPS in 
10% DMEM + P/S media. At t = 4 hrs, media was changed and 5 mM ATP (pH adjusted 
to 7.4) was added to fresh media and added to cells for 5 minutes. Lysates were collected 
directly in 1x laemmli buffer (section 2.2.1), boiled for 5 minutes, and loaded on gel for 
western blot analysis.  
The following protocol was used for precipitation of protein from cell culture 
media for western blot, and adapted from 87: 
 
1. Add 1 volume of Trichloroacetic acid (TCA) (100% w/v) to 4 volumes of protein 
sample.  
2. Shake and incubate 10 min at 4°C.  
3. Spin tube in microcentrifuge at 14,000 rpm for 5 min.  
4. Remove supernatant, leaving protein pellet intact. Pellet should be formed from 
whitish, fluffy ppt.  
5. Wash pellet with 200 ul ice-cold acetone.  
6. Spin tube in microcentrifuge at 14,000 rpm for 5 min.  
7. Repeat steps 4-6 for a total of 2 acetone washes.  
8. Dry pellet by placing tube in 95°C heat block for 5-10 min to drive off acetone, and 
resuspend in 1-2x laemmli buffer, boil for 5 minutes, and load on gel for western blot 
analysis.  
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3.2.2 Design and synthesis of methoxy-d4T 
 
Synthesis was commissioned to Tocris (Bristol, United Kingdom). A schematic of 
the synthesis is depicted in Fig. 3.2. Figs. 3.2-3.3 (quality control assays) performed by 
Tocris. The first batch of compound was poorly water-soluble compared to unmodified 
d4T. Subsequently, we dissolved the compound in 100% DMSO to create a concentrated 
stock solution.     
3.2.3 Lentivirus replication assay 
 
100 µM d4T or me-d4T was added to HeLa cells two hours before addition of a 
lentivirus-GFP particle (generated at the University of Kentucky; Dr. M. Mendenhall) at 
a multiplicity of infection of 10. At 24 hours an additional 100 µM d4T or me-d4T was 
added to cells, and at 48 hours cells were briefly fixed in 4% PFA (1-2 minutes) and 
washed with 1x phosphate buffered saline before imaging. Technical assistance with 
imaging provided by Bradley Gelfand (University of Kentucky). For cell counting of 
GFP-positive cells, four fields were chosen at random for each condition, images were 
processed at the same threshold, and GFP-positive cells were counted using ImageJ.  
3.2.4 Quantitative polymerase chain reaction 
 
Total DNA was extracted from cells and amplified by real-time quantitative PCR 
(Applied Biosystems 7900 HT Fast Real-Time PCR system) with Power SYBR green 
Master Mix. Oligonucleotide primers specific for mouse mtDNA COX1 (F 5’ TTC GGA 
GCC TGA GCG GGA AT 3’; R 5’ ATG CCT GCG GCT AGC ACT GG 3’) were used 
and normalized to a genomic DNA exon-intron junction of the gene Dicer1 (F 5’ GTG 
AGG CGG GCT CCC TGC TG 3’; R 5’ CTT CGA ACG CGG AAC GGG ACC 3’). The 
qPCR cycling conditions were 50 °C for 2 min, 95 °C for 10 min followed by 40 cycles 
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of a two-step amplification program (95 °C for 15 s and 58 °C for 1 min). At the end of 
the amplification, melting curve analysis was applied using the dissociation protocol from 
the Sequence Detection system to exclude contamination with unspecific PCR products. 
Relative expressions of target genes were determined by the 2 - ΔΔCt method. 
3.2.5 Western blot  
Please refer to section 2.2.2.  
3.2.6 Mice 
Please refer to section 2.2.3.  
3.2.7 Alu-induced model of RPE degeneration and mouse drug 
administration  
Please refer to section 2.2.4.  
3.2.8 Fundus photography   
Please refer to section 2.2.5.   
3.2.9 RPE flat mount, ZO-1 staining and confocal imaging 
Please refer to section 2.2.6.  
3.2.10 Liquid chromatography/Mass spectrometry 
 
HPLC was run using a 2 Varian ProStar model 210 HPLC solvent delivery 
module and a Phenomenex Kinetix C-18 column (100 mm x 2.1 mm x 2.6 µM). Solvent 
compositions were (A): 3 mM Ammonium formate and 10 mM N,N-dimethylhexylamine 
in H20; (B): 1:1 acetonitrile:H2O with 3 mM Ammonium formate and 10 mM N,N-
dimethylhexylamine. HPLC mobile phase and flow rate are listed in Table 3.1.   
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Time (min) A % B% Flow (mL/min) 
0 95 5 0.2 
3 95 5 0.2 
25 40 60 0.2 
26 0 100 0.2 
29 0 100 0.2 
30 95 5 0.2 
40 95 5 0.2 
Table 3.1. LC/MS parameters. HPLC mobile phase and flow rate.   
 
Mass Spectrometry was performed on a Varian 1200 L quadrupole MS/MS. Analytes 
were analyzed with electrospray ionization on negative mode. Cell extracts from Raji TK-
/+  cells were prepared by adding 40% acetonitrile/20% methanol/20% water to cell 
pellets, incubation at -20 °C for 15 minutes followed by centrifugation at 4 °C for 5 
minutes at 20,000 x g. Two sequential extractions were performed per cell pellet, pooled, 
and stored at – 80 °C until analysis. Technical assistance provided by John May 
(University of Kentucky).  
3.2.11 Fisher’s exact test for fundus photograph analysis 
 Please refer to section 2.2.9.  
 
3.3 Results 
3.3.1 Methoxy-d4T does not inhibit polymerases 
 
In order to test whether reverse transcriptase inhibition was required for 
inflammasome blockade by d4T, we synthesized a novel 5’ O-methyl-modified version 
of d4T (5’-OCH3-d4T; me-d4T) (Fig. 3.2 a; Figs. 3.3-3.4). Only the triphosphate forms 
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of nucleoside analogs inhibit reverse transcriptase; the methyl modification at the 5’ 
position prevents phosphorylation and thus formation of nucleoside triphosphate, as has 
been demonstrated in previous work using short-interfering RNAs 88. As predicted, me-
d4T did not inhibit reverse transcriptase using a lentivirus replication assay. A detailed 
methodology of this assay can be found in Section 3.2.3; the principle of this assay is, 
briefly, that the particles used in this assay contain RNA lentiviruses that require reverse 
transcription for conversion to their DNA form, and only then are able to express a green 
fluorescent protein encoded by the virus. In contrast to unmodified d4T, me-d4T did not 
block lentivirus reverse transcription in HeLa cells as monitored by a GFP reporter (Fig. 
3.2 b-c). Moreover, the triphosphate metabolite of di-deoxy nucleoside analogs causes 
depletion of mitochondrial DNA: NRTI-triphosphates are incorporated into a growing 
strand of mitochondrial DNA by DNA polymerase gamma, and the lack of a 3’ hydroxyl 
group halts strand elongation and leads to abortion of the nascent DNA strand synthesis 
85,89,90. Consistent with the idea that me-d4T is not phosphorylated, we found that d4T, 
but not me-d4T reduced mtDNA levels as measured by quantitative PCR for the Cox1 
mtDNA gene and normalized to genomic DNA by quantitative PCR for an exon-intron 
junction (at a locus within Dicer1) in primary mouse RPE cells (Fig. 3.2 d) after 48 hours 
of drug exposure.    
3.3.2 Methoxy-d4T blocks inflammasome activation and prevents RPE 
degeneration 
 
Remarkably, despite its inability to inhibit polymerases, me-d4T still blocked 
Caspase-1 activation in primary human RPE cells (Fig. 3.2 e). We confirmed that me-d4T 
also prevented Alu-induced RPE degeneration in wild-type mice (Fig. 3.2 f; p = 0.03; n = 
4 eyes/group). Four of four eyes from me-d4T-treated mice were protected against Alu-
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induced RPE degeneration, whereas all four eyes from vehicle-treated mice exhibited 
degeneration. These data indicate that d4T can block Caspase-1 activation and RPE 
degeneration independent of reverse transcriptase inhibition.  
3.3.3 NRTIs block LPS/ATP-induced inflammasome activation 
 
We also tested whether NRTIs blocked inflammasome activation by 
lipopolysaccharide (LPS; a component of the cell wall of gram negative bacteria) and 
ATP, a stimulus not known to signal via reverse transcriptase 29,91,92. After stimulating 
primary mouse bone marrow-derived macrophages with 1000 ng/mL LPS for four hours, 
the addition of ATP (5 mM in serum-free media) induced secretion of the active p20 
form of Caspase-1 into the cell culture media. Cell culture media was concentrated with 
trichloroacetic acid and immunoblotted for Caspase-1. Data were normalized to western 
blot of pro-Caspase-1 levels in cell lysates, collected directly in 1x laemmli buffer. We 
found that d4T inhibited LPS/ATP-induced Caspase-1 maturation (Fig. 3.4 a), consistent 
with preliminary data that d4T blocked Caspase-1 maturation in primary human RPE 
cells (Fig. 3.1).   
Utilizing a second system in which another NRTI, AZT, was rendered not 
competent for phosphorylation, we tested whether AZT could block LPS/ATP-induced  
inflammasome activation in thymidine kinase-deficient (Raji/TK-) cells, which do not 
phosphorylate AZT 82. After addition of AZT, thymidine kinase-expressing (TK+) 
parental cells, but not derivative TK- cells, produced AZT-triphosphate (AZT-TP), the 
AZT metabolite required for RT inhibition (Fig. 3.5 b; Figs. 3.6-3.8). One consequence 
of LPS/ATP-induced Caspase-1 activation is the proteolytic cleavage, maturation and 
secretion of interleukin 1 beta (IL-1 beta). Even though AZT was not phosphorylated in 
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TK- cells, AZT still inhibited LPS/ATP-induced interleukin-1 beta maturation (Fig 3.5 c), 
indicating that AZT did not inhibit interleukin-1 beta maturation via RT inhibition.   
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Figure 3.2 d4T blocks Alu-induced RPE degeneration and Caspase-1 activation 
independent of reverse transcriptase inhibition 
 
(A) Chemical structure of methoxy-d4T (me-d4T). A single substitution of the ribose 5’ 
hydroxyl group with a methoxy group (circled) designed to prevent d4T phosphorylation. 
See Figures 3.3-3.5 for detailed synthesis information.   
(B-C) Replication of a GFP-expressing lentivirus in HeLa cells was blocked by 
unmodified d4T, but not me-d4T (100 µM both drugs). (B) Quantification of GFP-
positive cells per field of view, n = 4, *p < 0.05 by Student’s t-test. (C) Representative 
images.    
(D) Unmodified d4T, but not me-d4T (100 µM both drugs), reduces mtDNA levels 
(normalized to chromosomal DNA exon-intron junction sequence) in primary mouse 
RPE cells as determined by real-time quantitative PCR. n=4, *p < 0.05 by Student’s t-
test.  
(E) Western blot of Caspase-1 activation (p20 subunit) in primary human RPE cells 
transfected with Alu RNA + me-d4T (25 µM).  
(F) Fundus photographs (top row) and flat mounts stained for zonula occludens-1 (ZO-1; 
red) (bottom row) show that me-d4T (intraperitoneal injection) prevented Alu-induced 
RPE degeneration in mice. In fundus photographs degeneration outlined by blue 
arrowheads. Representative images of n = 4 (C, E, F) shown. Scale bars, (C): 200 µm; 
(F): 20 µm. Fisher’s exact test p-value of (c) pAlu + vehicle vs. pAlu + me-d4T: 0.029.  
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Figure 3.3 Synthesis of me-d4T 
 
(A) Schematic overview of me-d4T synthesis.  
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 (B) HPLC chromatogram of me-d4T (peak # 6) final product, >97% purity.   
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Figure 3.4 Synthesis of me-d4T  
 
(A) 1H NMR spectroscopy of me-d4T final product, chemical shifts consistent with 
structure. 
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(B) Liquid chromatography/mass spectrometry of me-d4T final product, m/z ratio 
consistent with structure.  
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Figure 3.5 NRTIs block LPS/ATP-induced inflammasome activation 
 
(A) Western blot of cell culture media (normalized to pro-Caspase-1 in cell lysate) 
showing that d4T (100 µM) blocked Caspase-1 activation in LPS/ATP treated primary 
mouse bone marrow-derived macrophages.  
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 (B) Liquid chromatography-mass spectrometry (LC-MS), showing that Raji TK+ cells, 
but not Raji TK- cells, phosphorylate AZT (100 µM) to AZT-triphosphate (AZT-TP).  
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(C) Western blot of cell lysates showing that AZT (100 µM) blocks IL-1 beta activation 
by LPS/ATP in both Raji TK- and TK+cells. Representative images of n = 3-4 
experiments (A-C).  
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Figure 3.6 LC-MS/MS of AZT-TP and AZU-TP 
LC-MS/MS spectra of AZT-triphosphate (AZT-TP, target compound; top) and AZU-
triphosphate (AZU-TP, internal standard; bottom). 
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Figure 3.7 AZT-TP and AZU-TP separation by liquid chromatography 
Chromatographic separation of Raji TK- cells spiked with AZT-TP (top) and AZU-TP 
(bottom) with MS spectra (insets) to confirm identity of designated peaks. 
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Figure 3.8 AZT-TP formation in Raji TK+ cells 
Standard curve of AZT-TP standards (black circle). Raji TK+ samples treated with AZT 
(100 µM) produced AZT-TP (white triangles), whereas AZT-TP was not detectable in 
Raji TK- cells treated with AZT.  Representative of two experiments.  
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3.4 Discussion  
3.4.1 NRTI-induced mtDNA depletion 
 
Phosphorylation of NRTIs is mediated by intracellular kinases. NRTI-
triphosphates (NRTI-TPs) are the active metabolites that prevent synthesis of an 
elongating strand of complementary DNA because NRTI-TPs lack a 3’OH that is 
required for addition of subsequent nucleotides by reverse transcriptase. As discussed in 
Chapter 2, NRTI-TPs inhibit a range of enzymes besides reverse transcriptases, including 
various host cell DNA polymerases.   
Off-target effects of NRTIs in HIV patients are typically attributed to off-target 
effects through inhibition of non-RT polymerases, in particular DNA polymerase gamma, 
which is responsible for replicating mitochondrial DNA (mtDNA). In support of this 
hypothesis, NRTIs have greater affinity for DNA polymerase gamma than other host 
polymerases (section 3.1.2). Furthermore, mtDNA depletion occurs in symptomatic 
tissues in patients taking NRTIs, and discontinuation of NRTIs leads to a rescue of 
mtDNA abundance. This rescue of mtDNA levels correlates directly with resolution of 
symptoms. Finally, molecular modeling studies also corroborate the DNA polymerase 
gamma hypothesis of NRTI toxicity (reviewed in 93).    
Although increased cytoplasmic levels of oxidized mtDNA can activate the 
NLRP3 inflammasome 86, NRTI-induced reduction in mtDNA levels probably do not 
account for the observed inflammasome inhibition for several reasons. For one, a version 
of d4T (methoxy-d4T; Me-d4T) that did not affect mtDNA levels (unlike unmodified 
d4T), but still blocked Alu-induced Caspase-1 activation in primary human RPE cells. 
The lack of effect by Me-d4T on mtDNA levels is consistent with the methoxy 
modification blocking phosphorylation; this result is also consistent with the finding that 
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Me-d4T did not block lentivirus replication (Fig. 3.2). Furthermore, the time-course of 
experiments is not long enough for NRTIs to exhibit considerable reductions in mtDNA. 
For example, no considerable decrease in mtDNA is observed after 24 hours in Alu RNA 
transfection experiments (Fig. 3.9 a), nor four hours after d4T exposure during the time-
course of LPS/ATP experiments (Fig. 3.9 b). In each experiment, cells were treated 
exactly as in experiments to detect inflammasome activation by western blot (see 
methods, Section 3.2.1). Finally, we found that several mtDNA-sparing NRTIs (3TC, 
ABC) 89,90,93 block Alu-induced Caspase-1 activation, indicating that reduction of mtDNA 
levels is not a common mediator of the protective anti-inflammatory class effect of 
NRTIs. The use of Me-d4T, or other nucleoside analogs that exhibit little to no effect on 
mtDNA levels, could be an effective therapeutic strategy to avoid off-target 
mitochondrial effects.  
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Figure 3.9. d4T does not affect total mtDNA levels over the time-course of 
experiments. D4T treatment of primary human RPE cells A) transfected with Alu RNA 
(t = 24 hrs) or B) after LPS (1000 ng/mL) treatment (t = 4 hrs) did not considerably alter 
total mtDNA levels as detected by real-time quantitative PCR. n = 2, error bars represent 
standard error.  
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3.4.2 Reverse transcriptase-independent inhibition of NLRP3 
inflammasome 
 
In addition to showing that a phosphorylation-incompetent version of d4T 
blocked inflammasome activation and RPE degeneration, we further ruled out reverse 
transcriptase as a mechanism of NLRP3 inflammasome inhibition by NRTIs by showing 
that d4T and AZT blocked IL-1 beta secretion by LPS/ATP, a stimulus which is not 
known to signal through reverse transcriptase (Fig. 3.1). To show that AZT-triphosphate 
does not mediate the inhibition of LPS/ATP-induced inflammasome activation, we used 
the Raji TK-/+ B cell lymphoma cell line. Raji TK+ cells are the parental line from which 
Raji TK- cells are derived via selection with 5-bromo-dUrd 94-96. We confirmed previous 
reports that Raji TK- cells do not convert AZT to AZT-TP, whereas Raji TK+ cells do 
(Fig. 3.1). In unpublished data, we also performed an experiment using 10 times the 
numbers of Raji TK- cells as shown in Fig. 3.1, and still did not detect AZT-TP in TK- 
cells by LC-MS. The great disparity in AZT-TP synthesis in these two Raji cell lines 
suggests that AZT-TP does not mediate inhibition of IL-1 beta maturation after LPS/ATP 
challenge.  
Although B cells (e.g. Raji cells) are not a widely-used model system for NLRP3 
inflammasome activation, we were able to detect mature IL-1 beta as a marker of 
inflammasome activation in this system. There is precedent that B cells express (albeit 
weakly) NLRP3, which can induce IL-1 beta maturation 97, and also that LPS/ATP-
induces Caspase-1 activation in B-cells 98. The utility of this model beyond as a system 
for interrogating RT inhibition-independent AZT function is not clear.  
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3.4.3 Chromatographic separation of AZT and AZT-TP 
 
We developed our own method for separating AZT and AZT-TP 
chromatographically, based previous work by others 99. The details methodology of this 
protocol can be found in Section 3.2.10 and in Figs. 3.6-3.8. Such a technique has major 
implications for patients taking NRTIs in terms of optimizing dosing regimens, although 
they have not yet been translated into clinical practice. The importance of separating AZT 
and AZT-TP chromatographically is based in the idea that the conversion of NRTIs to 
their NRTI-TP metabolite is thought to be a critical process in the blockade of HIV 
replication 99. However, NRTIs have a relatively narrow therapeutic window, and the 
adverse events due to NRTI toxicity are numerous, debilitating, and a major cause of 
poor adherence to therapy, which leads to viral resistance to NRTIs 100. Currently, clinical 
practice involves administering a fixed dose of NRTI based on an “over-under” weight 
cut-off (60 kg), without regard to inter-individual differences in NRTI metabolism. 
Therefore, optimization of a patient’s NRTI dose based on a direct measurement of NRTI 
metabolism to NRTI-TP would help determine a best-practice dosing regimen (minimize 
adverse effects while maximizing therapeutic efficacy).   
 
3.4.4 IL-1 beta vs. IL-18 in AMD 
 
 In the Alu-induced model of RPE degeneration, we showed that IL-18, and not 
IL-1 beta, was a key mediator of RPE degeneration 28. However, the role of IL-1 beta has 
been shown as an effector in other models of NLRP3 activation in the RPE by other non-
Alu stimuli (see section 2.4.1). Since Caspase-1 is required for the maturation of both IL-
18 and IL-1 beta, and because NRTIs function upstream of Caspase-1 to prevent IL-1 
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beta maturation, we predict that NRTIs will also block other AMD models driven by the 
NLRP3 inflammasome and IL-1 beta.   
3.4.5 NLRP3 and HIV 
 
 The role of the NLRP3 inflammasome in driving or protecting against HIV 
pathogenesis is not well defined, except for a few initial studies. Some have speculated 
that HIV activation of the NLRP3 inflammasome is a protective effect that is lost in HIV-
infected individuals, because HIV induces expression of NLRP3 and IL-1 beta secretion 
from dendritic cells from HIV-infected individuals, but not healthy individuals 101. Others 
have shown that HIV induces NLRP3 expression and IL-1 beta secretion from human 
primary monocyte-derived macrophages 102. This hypothesis is based on findings that 
NLRP3 activation is a guardian against infection by other viruses 103.   
 Whether NLRP3-dependent or not, a role for Caspase-1 in modulating against 
HIV pathogenesis was recently described 104,105. In short, these papers showed that 
Caspase-1 sensing of abortive HIV infections (i.e. incomplete HIV reverse transcripts in 
the cytoplasm) in CD4+ T cells leads to their death. The authors of these works speculate 
this seemingly protective response to clear infected cells might actually be undermined 
by HIV, as the Caspase-1-induced inflammatory cell death recruits uninfected cells to the 
locus of inflammation thereby enabling spread of the virus.   
 It is not known whether NRTIs modulate Caspase-1 activity in HIV. One clue 
suggesting that NRTIs inhibit Caspase-1 activity is that HIV patients have increased 
plasma IL-18 levels 106,107, which decrease after treatment with NRTI-containing highly 
active anti-retroviral therapy 108. A possible mechanism could involve NRTI-mediated 
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reduction of the number of abortive infections (as above), thereby dampening Caspase-1 
activation.    
However, given our findings, it will be important for future work to determine not 
only whether NRTIs modulate Caspase-1 activation in HIV, but also whether such 
inhibition is dependent on reverse transcriptase inhibition. Tools such as methoxy-d4T 
and the Raji TK- cell system would be useful in answering this question. Interestingly, 
reduction of plasma IL-18 levels by NRTI treatment of HIV-1 infected patients did not 
significantly associate with viral load or CD4+ T-cell counts, consistent with the idea that 
NRTIs can dampen IL-18 levels before inhibition of viral replication occurs 108.  
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Chapter 4: NRTIs selectively block P2X7 pore function and P2X7-driven models of 
graft rejection and sterile liver inflammation 
4  
4.1 Introduction  
 
In Chapter 3 we established a proof-of-principle that d4T can inhibit the NLRP3 
inflammasome without reverse transcriptase inhibition. The goal of the work in Chapter 4 
is to gain a refined understanding of the mechanism of NRTI-mediated inflammasome 
inhibition using d4T as the model inhibitor. Since NRTIs block Caspase-1 activation, we 
looked at upstream mediators of inflammasome activity in the Alu model. Our efforts 
focused on the cell-surface receptor P2X7, which is a common mediator of NLRP3 
inflammasome activation by many stressors (see section 4.4). 
 
4.2 Methods and materials 
4.2.1 ATP assay 
 
Primary human RPE cells were transfected as in section 2.2.1, in serum-free 
DMEM. Cell culture supernatant was collected from cells, and centrifuged for 10 minutes 
at 300 x g in order to remove cell debris. Supernatants were mixed with an ATP-
dependent luciferase reaction (Enliten ATP assay (Promega)), and fluorescence was 
measured in a BioTek Synergy 4 plate reader, according to manufacturer’s instructions.  
4.2.2 Cell-permeant and –impermeant d4T variants 
 
Cell-permeant and –impermeant d4T variants were generously provided by Dr. 
Keykavous Parang (University of Rhode Island) 109. See also Fig. 4.3 c-d.   
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4.2.3 YO-PRO-1 assay 
  
YO-PRO-1 iodide was purchased from Invitrogen. HEK293 cells stably 
expressing the human P2X7 receptor (generously provided by George Dubyak, Case 
Western Reserve University) were cultured in G418+ (400 µg/mL) DMEM with 10% 
fetal bovine serum. Cells were trypsinized, and pellets were washed twice in 1x HBSS 
(without calcium and magnesium). Resuspended cells were plated at 50 x 105 cells/well 
on a 96 well black-walled cell culture plates spotted with A438079 or d4T to a 
concentration 64 µM. Cells were incubated at 37 °C and 5% CO2 for 30 minutes before 
addition of bzATP (100 µM) for 5 minutes, followed by YO-PRO-1 addition (2.5 µM) 
after which plates were read immediately for fluorescence (485 ex/530 em) every 30 
seconds for 5 minutes in a BioTek Synergy 4 plate reader.        
4.2.4 Electrophysiology 
 
Electrophysiology experiments were performed by collaborators Mark T. Young 
and Marta Radwan (Cardiff University, Wales, U.K.). Whole-cell patch-clamp recordings 
were made at room temperature using borosilicate glass pipettes (World Precision 
Instruments, Sarasota, FL, USA) which had resistances of 3–5 MΩ when filled with a 
solution containing the following (in mM): 145 NaCl, 10 EGTA and 10 HEPES, with the 
pH adjusted to 7.3 with NaOH. The recording chamber was continually perfused with 
extracellular saline solution (ECS) containing (in mM): 147 NaCl, 2 KCl, 1 MgCl2, 2 
CaCl2, 10 HEPES and 13 glucose, with the pH adjusted to 7.3 with NaOH. To obtain 
larger whole-cell currents by relieving divalent cation inhibition of P2X7 receptors 110, 1 
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mM ATP, 100 µM d4T and 1 mM ATP + 100 µM d4T were made in ECS with low 
concentrations of divalent cations (ECS-LD) containing (in mM): 147 NaCl, 2 KCl, 0.2 
CaCl2, 10 HEPES and 13 glucose, with the pH adjusted to 7.3 with NaOH . Current 
recordings were made at a holding potential of −60 mV using an Axon Instruments 
Axopatch Multiclamp 700A amplifier and Digidata 1322A A/D interface (Molecular 
Devices, Sunnyvale, CA, USA). Agonist applications were made at 90-s intervals. 
Compounds were applied to patch-clamped cells by means of a rapid perfusion system 
(RSC-160, Biologic, Claix, France), allowing solution exchange times in the range 20–
100 ms.  
4.2.5 Bone Marrow Transplant 
 
Murine model of graft versus host disease was performed by collaborators Shoba 
Amarnath and Daniel H. Fowler (National Institutes of Health, Bethesda, MD, U.S.A.).  
Bone marrow (BM) cells from B6 mice were harvested and T-cell depleted (T-depleted; 
anti-CD90 [Thy1.2] microbeads (Miltenyi Biotec). Host allogeneic recipients (BALB/c) 
were conditioned with TBI of 950 cGy. BALB/c mice were rescued with 10M B6.T-
depleted BM (TDBM) cells alone or together with 2.5M bulk T cells (CD4+) from 
B6.WT mice.  Murine recipients that were reconstituted with TDBM and CD4+ T cells 
were additionally treated for 10 days with either saline or stavudine (25 mg/kg/day) via 
i.p injections; stavudine was initiated at either day -1 or day 0 of BMT, as indicated in 
figure legend. Survival and clinical manifestations of GVHD were monitored. 
4.2.6 Sterile liver inflammation model 
 
Neutrophil migration in the sterile liver inflammation model was performed by 
Keir Pittman and Paul Kubes at the University of Calgary (Calgary, Canada). Prior to 
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each experiment, d4T (400 mg/kg) or control saline was administered via jugular vein 
approximately 20 minutes prior to burn. Mice were anaesthetized with a solution 
containing ketamine hydrochloride (200 mg/kg) and xylazine hydrochloride (10 mg/kg), 
via intraperitoneal injection, per the University of Calgary Animal Use Protocol.  The 
jugular vein was exposed and canulated for administration of additional anaesthetic and 
for administration of the compound or vehicle.  Following administration of compound or 
vehicle, a midline laparotomy was performed and a ~2.5 centimeter diameter section of 
skin and peritoneum were removed from the ventral surface of the abdomen, exposing the 
organs of the peritoneum. An electro-cautery probe fitted with a 30 gauge needle bent at a 
90° angle was used to induce a single focal injury on the ventral surface of the left lobe of 
the liver. Two hour recordings at 4x magnification were undertaken, using both green 
(LysMeGFP+ cells) and red (autofluorescensce) channels (exposure times of 400 ms 
respectively). Images were analyzed using ImageJ software and the number of GFP+ 
objects per field of view was determined as in 111. 
4.2.7 Statistical analysis 
 
  Results are expressed as mean + standard error of the mean (SEM), with p values 
< 0.05 considered statistically significant. Differences between groups were compared by 
Mann-Whitney U test, Student’s t test, or two-way ANOVA with Student-Newman-Keul 
post-hoc test, as appropriate, and two-tailed p values are reported. Survival analysis was 
performed according to the Kaplan-Maier method and survival curves were compared 
using log-rank test.   
4.2.8 MitoSOx assay 
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MitoSox Red dye was obtained from Invitrogen and used according to the 
manufacturer’s instructions. Briefly, MitoSOx Cells is a mitochondria-targeting 
fluorogenic dye that is rapidly oxidized by superoxide but less so by other reactive 
oxygen species. Upon oxidation MitoSOx binds to nucleic acids and fluoresces. Cells 
were imaged 15 hours after Alu transfection, as described in section 2.2.1.  
4.2.9 ELISA 
 
Human interleukin-1 beta ELISA was purchased from R & D. Assay was 
performed according to the manufacturer’s instructions.  
 
4.3 Rationale and results 
4.3.1 Alu RNA induces ATP release from human RPE cells 
 
Alu RNA 30 and LPS/ATP 112 both activate the NLRP3 inflammasome via the 
ATP receptor P2X7. We therefore hypothesized that d4T blocks P2X7 or a P2X7-
dependent pathway. First, we tested whether d4T acted upstream of P2X7 by modulating 
ATP release from cells. To test this idea, we measured ATP in serum-free media after 
transfection of primary human RPE cells with Alu RNA using an ATP-dependent 
luciferase reaction kit (section 4.2.1). ATP levels peaked at 4 and 6 hours after Alu RNA 
transfection, however, d4T did not block this extracellular release of ATP induced by Alu 
RNA (Fig. 4.1 a). 
4.3.2  d4T does not affect P2X7 channel function 
 
Since d4T did not affect ATP release, we hypothesized that d4T worked just 
downstream of this event to directly antagonize P2X7 function. There are two well 
described functions for P2X7 upon ATP binding, both of which are linked to NLRP3 
inflammasome activation: 1) Non-selective cation channel flux directly through P2X7; 
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and 2) Pore function, or increased cell permeability to large molecules up to ~1000 Da 
(nomenclature is confusing, as “pore” is typically used to define ion flux; however, in this 
case, the term “pore” will be used instead, consistent with the literature, to refer to this 
increased cell permeability to large molecules). 
Since P2X7 is a non-selective cation channel, its activation leads to potassium 
efflux from the cell. Potassium efflux has been suggested as a common mechanism of 
multiple NLRP3 inflammasome stressors 113-115, 116. However, d4T did not affect cation 
flux (Fig. 4.1 b-c) as monitored by whole-cell patch clamp analysis of HEK293 cells 
transiently transfected with either the human or rat P2X7 receptor upon ATP stimulation 
(Fig. 4.1 b-c; experiments performed by M. Radwan and M. Young, Cardiff University, 
United Kingdom), indicating that d4T does not inhibit Alu-induced inflammasome 
activation via modulation of P2X7-mediated potassium flux.  
4.3.3 d4T blocks P2X7-dependent dye uptake  
 
P2X7 activation is also associated with the formation of a large pore that is 
permeable to molecules of up to ~ 1,000 Da 117-119. The rapid (within seconds) uptake of 
large dyes, such as YO-PRO-1 iodide, is a gold standard assay for P2X7 activation. The 
relevance of dye uptake to inflammasome activation is not clear; dye uptake may simply 
be a marker of P2X7 function. Although the link between dye uptake and inflammasome 
requires further elucidation, we implicate interference with P2X7-mediated dye uptake as 
a mechanism of blocking Alu-induced inflammasome activation.  
YO-PRO-1 is a dye that fluoresces upon nucleic acid binding; an increase in 
fluorescences occurs upon YO-PRO-1 entry into cells, where it binds nucleic acids. We 
found that d4T and the known P2X7 antagonist A438079 inhibited rapid P2X7-
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dependent uptake of the fluorescent dye YO-PRO-1 iodide (M.W. 629 Da) in a human 
P2X7-overexpressing HEK293 stable cell line (Fig. 4.1 d) after addition of a benzoylated 
version of ATP (bzATP) that is a highly selective agonist for P2X7. Non-P2X7 
expressing HEK293 cells (Fig. 4.2) did not exhibit bzATP-induced YO-PRO-1 dye 
uptake as measured by fluorescence. 
4.3.4 Selective P2X7-dependent pore antagonism blocks Alu-induced 
inflammasome activation 
 
Interestingly, d4T only partially inhibited YO-PRO-1 uptake compared to 
A438079, whereas Alu RNA-induced Caspase-1 activation was completely blocked by a 
small peptide targeting the P2X7-associated Pannexin-1 channel, which inhibits P2X7-
dependent dye uptake and LPS/ATP-induced inflammasome activation, but not cation 
flux 120 (Fig. 4.3 a). These data are consistent with the idea that P2X7 activation leads to 
activation of multiple cell permeabilization pathways 121, and that inhibition of some but 
not all of these pathways by d4T is sufficient to fully block Caspase-1 activation.   
Conversely, Alu RNA-induced Caspase-1 activation was not inhibited by calmidazolium, 
which selectively blocks P2X7-mediated cation flux but not dye uptake (Fig. 4.3 b). This 
result is consistent with the idea that inhibition of P2X7-dependent pore function by d4T, 
and not cation channel modulation, is responsible for the protective effects of d4T in Alu 
RNA-induced inflammasome activation.    
4.3.5 d4T requires cell entry to block Alu-induced inflammasome activation 
 
There are many lines of evidence indicating that the intracellular C-terminus of 
P2X7 selectively governs dye uptake function, and is not or is less essential for 
modulating P2X7 cation function. For one, deletion of the last 177 (C-terminal) amino 
acids in P2X7 abrogates dye uptake without affecting cation channel function 117,122. 
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Numerous other deletions and point mutations in C-terminal intracellular domains of 
P2X7 abrogate pore formation; some of these disruptions alter cell-surface expression 
and cation function, but in others these characteristics are maintained 123-125, therefore 
implicating the C-terminus of P2X7 as a key regulator of P2X7 dye uptake function. We 
hypothesized that if d4T requires cell entry to block Caspase-1 cleavage, then this would 
be consistent with the idea that d4T modulates P2X7 C-terminus function. Indeed, a 
version of d4T that is not cell permeable 109 did not block Caspase-1 activation by Alu 
RNA in primary human RPE cells, whereas a version of d4T that readily permeates cells 
very effectively blocked Caspase-1 activation (Fig. 4.3 c-d).  
4.3.6 d4T blocks Alu-induced mitochondrial ROS 
 
Consistent with antagonism downstream of P2X7 but preceding inflammasome 
activation, d4T blocked Alu-induced mitochondrial ROS (mtROS) production 28 as 
measured by MitoSOx assay (Fig. 4.3 e; method detailed in Section 4.2.8).  
4.3.7 d4T does not block MSU-induced IL-1 beta secretion 
 
We hypothesized that if d4T antagonizes P2X7, then it would not prevent P2X7-
independent inflammasome activation. Previous work showed that crystalline 
monosodium urate (MSU) causes interleukin 1-beta secretion independent of P2X7 
126,127. Following the same methodology from previous work, we treated THP-1 
monocytes with phorbol 12-myristate 13-acetate (PMA) overnight in order to 
differentiate them into macrophages. We treated these PMA-primed THP-1 cells with 
MSU, and measured IL-1 beta secretion to the cell culture supernatant by ELISA: we 
found that d4T did not significantly inhibit IL-1 beta secretion (Fig. 4.4) at a wide dose 
range of d4T. Collectively, these data indicate that d4T blocks P2X7-dependent 
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inflammasome activation via a mechanism involving selective inhibition of P2X7-
associated pore function.   
4.3.8 d4T is efficacious in a murine model of graft-versus-host-disease 
 
To explore the potential therapeutic relevance of NRTIs beyond the Alu RNA-
induced model of GA, we hypothesized that if NRTIs function as NLRP3 inflammasome 
inhibitors then they might be broadly useful in other animal models of disease that are 
also driven by P2X7. Murine graft-versus-host disease (GVHD) is NLRP3 
inflammasome- and P2X7-driven 128,129; consistent with these results, treatment of 
allogeneic bone marrow and T cell recipients (donor: C57Bl6 mice; recipient BALB/c) 
with d4T improved survival compared to saline treated controls (Fig. 4.1 e).  
Intraperitoneal administration of d4T starting one day before bone marrow transplant 
showed superior survival (70% vs. 0% (saline)) compared to d4T beginning on the day of 
transplant (30% vs. 0% (saline)), consistent with findings that inflammasome activation 
occurs very early on and dictates the development and severity of GVHD 128,129. 
4.3.9 d4T modulates neutrophil migration in a sterile liver injury model 
 
 Finally, we tested the efficacy of d4T in a model of sterile liver injury, which was 
previously shown to be dependent on NLRP3 and P2X7 111. In this model, a sterile, focal 
injury is performed by needle poke of the liver. The experiment is performed in LysM-
GFP+ mice, which express GFP under the control of the lysozyme M promoter, which is 
expressed at very high levels by neutrophils, and to a lesser degree macrophages and 
monocytes130. Neutrophils (GFP+ cells) are the primary cell type to invade the focus of 
injury within the first few hours. A bolus of intravenous d4T was delivered starting about 
half an hour before liver injury and reduced early neutrophil migration to the focus of 
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liver injury (Fig. 4.1 f; Fig. 4.4). Again, this finding is consistent with the idea that d4T 
antagonizes P2X7 signaling.    
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Figure 4.1 NRTIs selectively block P2X7 pore function and P2X7-driven models of 
graft rejection and sterile liver inflammation 
 
(A) d4T (100 µM) does not block Alu-induced ATP release from primary human RPE 
cells (n = 4).  
(B-C) Experiments performed by M. Radwan and M. Young (Cardiff University, United 
Kingdom). Whole-cell patch clamp of rat and mouse P2X7 receptors in HEK293 cells. 
Cells were pre-incubated in d4T for at least 1 minute prior to application of 1 mM ATP 
(also in the presence of d4T). Currents were recorded in solutions containing low 
concentrations of divalent cations (giving larger currents but causing delayed return of 
current to baseline after washout). (B) Histogram showing the mean current density 
recorded for rat P2X7 and mouse P2X7 in the absence (-) and presence (+) of 100 µM 
d4T. Error bars represent standard error of the mean (n = 6 for rat P2X7 and n = 3 for 
mouse P2X7). No significant difference to recorded currents was observed in the 
presence of d4T. (C) Representative current traces from rat P2X7 in the absence (red) and 
presence (black) and mouse P2X7 in the absence (blue) and presence (grey) of 100 µM 
d4T.  
(D) P2X7-mediated YO-PRO-1 dye uptake induced by bzATP (100 µM) in HEK293 
cells stably expressing the human P2X7 receptor was inhibited by d4T and A438079 (64 
µM for both drugs). Fluorescence values are baseline subtracted from cells without 
bzATP treatment. * bzATP vs. d4T; # bzATP vs. A438079, p < 0.05 by Student-Newman 
Keuls post-hoc test (n = 12).  
(E) Administration of Stavudine Starting From Day -1 Pre-transplant Protects Murine 
Recipients from Graft versus Host Disease. BALB/c mice were subjected to TBI 
	  
	   69	  
(950cGY) and then reconstituted with T depleted bone marrow (TDBM) from B6 donors. 
Cohorts (n = 10 per cohort) received either BM alone or BM plus bulk CD4+ T cells 
(2.5M) on the same day as the irradiation. Cohorts that received BM and bulk CD4+ T 
cells were additionally treated with either vehicle (saline) or drug (stavudine) from day -1 
or day 0 for a period of 10 days. Clinical manifestations of GVHD and overall survival 
were monitored post-BMT. Survival analysis was performed according to the Kaplan-
Maier method and survival between groups was compared using the log-rank test. Results 
were pooled from two independent experiments. Experiment performed by Shoba 
Amarnath (NIH).  
(F) d4T (400 mg/kg) inhibits P2X7-dependent neutrophil recruitment to sites of focal 
hepatic necrosis. n = 4, error bars S.E.M., p < 0.05 by Student-Newman Keuls post-hoc 
test. Experiment performed by Keir Pittman (University of Calgary).  
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Figure 4.2 bzATP induces P2X7-dependent YO-PRO-1 uptake 
(A) Western blot for P2X7 in HEK293 cells vs. HEK293 cells stably expressing the 
human P2X7 receptor.  
(B) bzATP did not induce YO-PRO-1 uptake in P2X7-deficient HEK293 cell. n= 2-3, 
representative of two independent experiments. 
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Figure 4.3 P2X7-dependent pore function mediates Alu-induced Caspase-1 
activation 
(A-C) Western blot of Caspase-1 activation (p20 subunit) in primary human RPE cells 
transfected with Alu RNA + (A) Short peptide (Panx110; 240 µM) that blocks P2X7 pore 
function but not cation flux (vs. scrambled peptide: Scr Panx110; 240 µM); (B) 
Calmidazolium, which blocks P2X7 cation flux but not pore function, did not block 
Caspase-1 activation induced by Alu RNA.   
(C) Western blot showing that cell permeable (IC) and unmodified (no tag) d4T, but not 
cell-impermeable (EC), blocked Caspase-1 activation (p20 subunit) induced by Alu RNA. 
All drugs administered at 100 µM. Representative of n = 3 experiments.   
(D) Chemical structure of IC- and EC-d4T used in (C).  
(E) Mitochondrial ROS visualized with MitoSox (Red) and cell nuclei with Hoechst 
(Blue), showing that d4T (100 µM) prevents pAlu-induced mitochondrial ROS 
generation in primary human RPE cells. Representative image of n = 3-4. 
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Figure 4.4 d4T does not inhibit MSU-induced IL-1 beta secretion 
ELISA of cell culture supernatants in PMA-primed THP-1 cells shows that d4T does not 
block MSU-induced IL-1 beta secretion (n = 3-4).   
 
 
Figure 4.5 d4T inhibits neutrophil chemotaxis after acute liver injury  
LysMeGFP cells/FOV around a sterile focal hepatic lesion. D4T (400 mg/kg) or PBS 
administered via jugular vein 20 minutes prior to injury. n = 4, error bars S.E.M., p < 
0.001 between groups vehicle vs. d4T by two-way ANOVA. Experiment performed by 
Keir Pittman (University of Calgary). 
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4.4 Discussion  
4.4.1 The role of P2X7 and ATP in Alu-induced inflammasome activation 
  
We suspected that d4T antagonized P2X7 or P2X7 signaling because previously 
we found that P2X7 is a critical mediator of Alu RNA toxicity 30. Also, the link between 
P2X7 as an upstream mediator of the inflammasome is well described, especially in terms 
of LPS/ATP activation of the inflammasome 112, which was blocked by NRTIs (Fig. 3.1).   
Canonically, P2X7 functions as an ATP receptor. Here we confirmed that Alu RNA 
indeed signals through ATP to induce Caspase-1 activation. Preliminary time-course 
experiments from 1-24 hrs revealed that ATP levels in cell culture media peaked at 4 and 
6 hours after Alu RNA transfection. However, d4T did not affect ATP release induced by 
Alu RNA (Fig. 4.1 a), indicating that it functions somewhere downstream of ATP to 
block Caspase-1 activation. It would be interesting to test whether other nucleoside 
analogs also block P2X7 function in terms of dye uptake or other P2X7-mediated 
functions. All NRTIs need not block Caspase-1 cleavage by the same mechanism.  
We showed that d4T antagonizes P2X7 function by blocking YO-PRO-1 dye uptake; 
whether d4T acts directly at P2X7 or targets a P2X7-interacting protein remains to be 
determined (see discussion in section 4.4.2). P2X7 heteromerizes with another ATP 
receptor, P2X4, to form functional complexes 131 ; future work could determine whether 
there is any role for P2X4 in mediating P2X7-dependent Alu-induced RPE degeneration. 
    We also showed that a mimetic peptide targeting Pannexin-1 has a protective 
effect in the Alu-induced model of inflammasome activation. Further work will also be 
required to confirm the relevance of Pannexin-1 in the Alu-induced model. This work is 
especially important in consideration of the fact that pannexin-1 targeting by mimetic 
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peptide and siRNA knockdown protects against LPS/ATP-induced inflammasome 
activation 120, whereas there is no protective effect from LPS/ATP in cells genetically 
deficient for P2X7 112. Such future approaches should include testing whether Alu RNA 
induces toxicity in Pannexin-1 knockout mice or after siRNA knockdown.  
4.4.2 P2X7 C-terminus and dye uptake 
 
The C-terminal tail of P2X7 contains multiple putative phosphorylation sites for 
cellular kinases, suggesting that such modifications could affect P2X7 receptor 
function/localization 123; others have shown that tyrosine phosphorylation of other 
proteins in the P2X7-interactome negatively regulate P2X7 function 132. Still other work 
shows that P2X7 activation results in its dephosphorylation 133, which affects interaction 
with its binding partners, including many cytoskeletal proteins. Signal transduction along 
microtubule rearrangement is a known mediator of NLRP3 inflammasome activation 134; 
it is tempting to speculate that the activity of d4T, and other NRTIs, could intersect with 
these signaling pathways.  Another interesting future direction would be to investigate the 
possibility that NRTIs, which are well-described kinase substrates, act as “dummy” 
substrates or act as kinase sinks to alter the intracellular kinome.  
4.4.3 Binding studies of d4T and P2X7 
 
There is considerable structural diversity of P2X7 antagonists 132, and common 
motifs or patterns that characterize P2X7 antagonism are not well defined. It is unclear if 
these antagonists bind directly to P2X7, an issue that remained unresolved in part due to 
the lack of a published P2X7 crystal structure. Although the P2X7 receptor has not been 
crystallized, it has been modeled based on homology with the crystal structure P2X4 
zebrafish 135,136. Future bioinformatics analyses could use this model to predict NRTI 
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binding to P2X7. The residues critical for nucleotide binding by P2X7 have been 
described, including the key residues involved in ATP binding 135,137. Interestingly, 
although ADP does not bind P2X7, a ribosylated version of ADP does covalently bind 
and activate P2X7 138-140. This ATP-independent P2X7 activation is mediated by 
extracellular NAD+ (which is converted to ADP-ribose). It is tempting to speculate that 
multiple NRTIs could modulate P2X7 receptor activation by virtue of their common 
ribose motif.  
We were unsuccessful in two binding assays to show interaction of d4T with 
P2X7. First, we attempted to detect binding of carboxyfluorescein-conjugated d4T to 
recombinant full-length P2X7 protein (Novus Biologicals). Several limitations could 
explain why no binding was detected by this approach. For one, the protein was purified 
from an in vitro wheat germ expression system; perhaps requires d4T interaction with 
P2X7 requires mammalian-specific post-translational modifications. Another possibility 
is that the carboxyfluorescein tag could have altered d4T binding. We were also 
unsuccessful in our attempt to detect interaction by incubating P2X7 immunoprecipitate 
with fluorescent-conjugated d4T. This approach, as with attempt with the recombinant 
P2X7 binding study, is limited by the fact that P2X7 forms homotrimeric membrane 
complexes, in addition to complexes with other P2 receptors (i.e. P2X4) 131. These 
complexes could have been disrupted or altered during protein extraction (second 
approach), or would not have been present (first approach). Attempts could be made to 
preserve these interactions, for example using purified membrane preparations 141. 
Alternative approaches for future investigation might include or combine techniques such 
as surface plasmon resonance, a “grind-and-bind” approach using whole cell lysates, in 
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situ imaging of labeled d4T comparing P2X7-overexpressing vs. –deficient cells, and 
using radiolabeled-d4T to overcome potential steric obstruction of binding by fluorescent 
tag molecule. Even if d4T or other NRTIs do not bind to P2X7, future work could also 
investigate whether d4T modulates P2X7 activity by altering its sub-cellular localization 
or trafficking 123,124,142. P2X7 is expressed in the RPE 143,144; future work could determine 
whether P2X7 levels are altered in AMD.  
4.4.4 NRTI function beyond the Alu RNA model 
 
To our knowledge, until now there have not been any reports of FDA-approved 
drugs that selectively target P2X7 dye uptake function without affecting cation channel. 
Interestingly, selective P2X7 pore inhibition (without cation flux modulation) was found 
to reduce a mouse model of neuropathic pain 145. This finding suggests that d4T (and 
possibly the other NRTIs tested herein) could be ideal drug repurposing candidates for 
neuropathic pain (or, in the future, other P2X7 pore-selective-pathies). Unfortunately, 
d4T is shown to induce pain in rodent models 146,147; however, even if d4T is not ideal 
candidate for selective P2X7 targeting in pain, other NRTIs that are not associated with 
pain induction in humans/animal models could be explored as potential therapeutics via 
P2X7 blockade.  
The extension of our work to animal models of graft-versus-host disease and 
neutrophil migration not only broadens the appeal and utility NRTI drug repurposing, but 
also promises to lend insight into the mechanism of anti-inflammatory NRTI function. 
The GVHD and neutrophil migration models exhibit overlapping mechanisms with the 
Alu-induced model, in that they are all mediated by ATP, P2X7 and NLRP3. Future 
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investigations could focus on the role of P2X7 pore function in these models to shed light 
on the mechanism of d4T on P2X7-dependent signaling.    
We showed that d4T had a dramatic protective effect on the mouse survival in an 
allogeneic bone marrow transplant graft-versus-host disease model (Fig. 4.1 e). Graft-
versus host disease is the major obstacle preventing successful tissue transplant 148,149. 
P2X7 also drives heart transplant rejection in humans and mice 150; however, for the most 
part, a therapeutic role for P2X7 inhibition in other transplant models remains to be 
determined.  
D4T also affected neutrophil migration to a focus of injury in a model of sterile 
liver inflammation, which is a major contributor to drug-induced liver injury and 
steatohepatitis, a major determinant of fibrosis and carcinogenesis 151; future work could 
determine the physiologic or pathologic ramifications of NRTI modulation of innate 
immune cell chemotaxis and function.  
 
4.4.5 P2X7 and HIV replication 
 
There is some evidence that P2X7 facilitates HIV replication 152. Therefore, our 
finding that NRTIs inhibit P2X7 should lead to a re-examination of the mechanistic basis 
of NRTI function in HIV therapy. Could the therapeutic response induced by NRTIs in 
HIV patients be explained in part by P2X7 inhibition? Methoxy-d4T would be an ideal 
tool to probe the relative contributions of reverse transcriptase inhibition vs. P2X7 
blockade in HIV replication. Since methoxy-d4T is not phosphorylated and therefore 
does not affect mitochondrial DNA levels, its use as an adjuvant in HIV patients would 
allow for P2X7 inhibition without the side effects attributable to inhibition of 
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mitochondrial DNA synthesis (see section 3.4.1). One could also probe the role of P2X7 
inhibitory activity of NRTIs in the absence of RT inhibition by testing whether AZT 
inhibits the replication of HIV (or other retroviruses with tropism for B cells) in Raji TK- 
cells 153.   
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Conclusion 
 
NRTIs are a diverse, widely used, inexpensive class of small molecules, with 
extensive pharmacokinetic and safety data collected over several decades of human use. 
Our work, by illustrating a novel mechanism of action of NRTIs, paves a clear path for 
the broad repurposing of this drug class to address major unmet medical needs: age-
related macular degeneration is a disease that affects tens of millions of people 
worldwide for which there is no effective treatment 1,154. Since inflammasome inhibition 
by NRTIs can be achieved without their phosphorylation, the use of me-d4T or other 
phosphorylation-incompetent nucleoside analogs to treat these diseases could avoid dose-
limiting toxicities associated with NRTI-triphosphate-mediated polymerase inhibition 55. 
Systemic side effects of NRTIs could also be avoided by local administration of NRTIs 
(i.e. intra-ocular injection or sustained-release ocular implant for AMD). Furthermore, as 
AMD is a disease that typically progresses slowly (over years), low-doses of oral 
administration may be therapeutic without dose-limiting side effects. It is not known 
whether chronic NRTI use is protective against developing AMD; however, as the 
population of aging HIV-positive individuals continues to grow, it might be possible to 
determine this predicted effect. 
Graft-versus host disease is the major obstacle preventing successful allogeneic 
hematopoietic stem cell transplantation 148. Also, neutrophil migration is a major 
contributor to drug-induced liver injury and steatohepatitis, which in turn is a major 
determinant of fibrosis and carcinogenesis 151. Future work should determine the 
physiologic or pathologic ramifications of NRTI modulation of innate immune cell 
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chemotaxis and function in a variety of disease models. Adverse effects associated with 
long-term NRTI use would be avoided with short-term NRTI use in acute conditions (i.e. 
acute GVHD or exacerbation of other inflammatory disease).        
A role for P2X7 in regulating HIV replication was recently proposed 152; of note, 
HIV patients have increased plasma levels of the inflammasome effector IL-18 106,107, 
which decrease after treatment with NRTI-containing highly active anti-retroviral therapy 
108. Interestingly, reduction of plasma IL-18 levels by NRTI treatment of HIV-1 infected 
patients was not significantly associated with viral load or CD4+ T-cell counts, thereby 
indicating that NRTIs can dampen IL-18 levels before inhibition of viral replication 
occurs. IL-18 maturation requires pro-IL18 cleavage by active Caspase-1, which typically 
also requires P2X7 activation. Thus, future work could address whether NRTIs can 
modulate HIV-induced cytokine expression/viral replication independent of reverse 
transcriptase inhibition.  
Interestingly, it has been reported that P2X7-dependent pore function alone can 
influence phenotype 145. However, to our knowledge, there are no FDA-approved drugs 
that selectively target P2X7 signaling and not ion channel activation. Therefore, NRTIs 
could be valuable clinically and experimentally in the selective targeting of P2X7 
function. 
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Appendix 
 
Sequence of Alu sequence used for synthesis of in vitro transcribed Alu RNA (in pUC18 
plasmid, gift of J. Goodrich). DraI cut site on plasmid is annotated at position 308.  
  
Sequence of Alu sequence in pAluA (in pUC19 plasmid, gift of J. Moran).  
 
  1        10        20        30        40        50 
   |        |         |         |         |         | 
   GGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTT 
   CGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCG 
   GAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCT 
   TTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCT 
   GTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAG 
   CCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCC 
   CAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGC 
   TGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAAT 
   TAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGC 
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   TTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACA 
   GGAAACAGCTATGACCATGATTACGCCAAGCTTGGGCTGCAGGTCGACTC 
   TAGAGGATCCCCCCCCCCCGCTCCCCAATGACGTAACTGCCCTGCAGCTT 
   CTAGTAGCTTTTCGCAGCGTCTCCGACCGGCCGGGCGCGGTGGCTCACGC 
   GTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAG 
   GAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAA 
   AAAAAATACAAAAAATTAGCCGGGCGTGGTAGCGGGCGCCTGTAGTCCCA 
   GCTACTCGGGAGGCTGAGGCAGGGGAATGGCGTGAACCCGGGAGGCGGAG 
   CTTGCAGTGAGCCGAGATCCCGCCACTGCACTCCAGCCTGGGCGACAGAG 
   CGAGACTCCGTCTCAAATCCCCTCAGAAGAACTCGTCAAGAAGGCGATAG 
   AAGGCGATGCGCTGCGAATCGGGAGCGGCGATACCGTAAAGCACGAGGAA 
   GCGGTCAGCCCATTCGCCGCCAAGCTCTTCAGCAATATCACGGGTAGCCA 
   ACGCTATGTCCTGATAGCGGTCCGCCACACCCAGCCGGCCACAGTCGATG 
   AATCCAGAAAAGCGGCCATTCTCCACCATGATATTCGGCAAGCAGGCATC 
   GCCATGGGTCACGACGAGATCCTCGCCGTCGGGCATGCGCGCCTTGAGCC 
   TGGCGAACAGTTCGGCTGGCGCGAGCCCCTGATGCTCTTCGTCCAGATCA 
   TCCTGATCGACAAGACCGGCTTCCATCCGAGTACGTGCTCGCTCGATGCG 
   ATGTTTCGCTTGGTGGTCGAATGGGCAGGTAGCCGGATCAAGCGTATGCA 
   GCCGCCGCATTGCATCAGCCATGATGGATACTTTCTCGGCAGGAGCAAGG 
   TGAGATGACAGGAGATCCTGCCCCGGCACTTCGCCCAATAGCAGCCAGTC 
   CCTTCCCGCTTCAGTGACAACGTCGAGCACAGCTGCGCAAGGAACGCCCG 
   TCGTGGCCAGCCACGATAGCCGCGCTGCCTCGTCCTGTAATTAGCAATAT 
   AATGAATTGCAGGGAAAAGTTATCAGGCATGCACCTGGTAGCTAGTCTTT 
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   AAACCAATAGATTGCATCGGTTTAAAAGGCAAGACCGTCAAATTGCGGGA 
   AAGGGGTCAACAGCCGTTCAGTACCAAGTCTCAGGGGAAACTTTGAGATG 
   GCCTTGCAAAGGGTATGGTAATAAGCTGACGGACATGGTCCTAACCACGC 
   AGCCAAGTCCTAAGTCAACAGATCTTCTGTTGATATGGATGCAGTTCACA 
   GACTAAATGTCGGTCGGGGAAGATGTATTCTTCTCATAAGATATAGTCGG 
   ACCTCTCCTTAATGGGAGCTAGCGGATGAAGTGATGCAACACTGGAGCCG 
   CTGGGACCTAATTTGTATGCGAAAGTATATTGATTAGGTTTGGAGTACTC 
   GAGTTCATTCAGGGCACCGGACAGGTCGGTCTTGACAAAAAGAACCGGGC 
   GCCCCTGCGCTGACAGCCGGAACACGGCGGCATCAGAGCAGCCGATTGTC 
   TGTTGTGCCCAGTCATAGCCGAATAGCCTCTCCACCCAAGCGGCCGGAGA 
   ACCTGCGTGCAATCCATCTTGTTCAATGGCCGATCCCATATTGGCTCGAC 
   CTCCAAAAAAGCCTCCTCACTACTTCTGGAATAGCTCAGAGGCCGAGGCG 
   GCCTCGGCCTCTGCATAAATAAAAAAAATTAGTCAGCCATGGGGCGGAGA 
   ATGGGCGGAACTGGGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCG 
   GGACTATGGTTGCTGACTAATTGAGATGCATGCTTTGCATACTTCTGCCT 
   GCTGGGGAGCCTGGGGACTTTCCACACCTGGTTGCTGACTAATTGAGATG 
   CATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACC 
   CTAACTGACACACATTCCACAGCCGTCTCAAAAAAAAAAAAAAAAAAAAA 
   AAAAAAAAAAAAAAAAAAAAAAACATGGGACTCAAAGTTTCAGCATCGCG 
   TCTCTTTTGCCGAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGA 
   AAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCG 
   CCAGCTGGCGTAATAGCG 
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Annotations:  
 
 
 
 
 
  
Name Start End Length
7SL/Promoter 563 628 66
AluA 629 917 289
AluA_End 2473 2523 51
Cloning/Vector 532 562 31
CloningVector 2524 2562 39
M13F 2568 2584 17
M13R 499 515 17
NeoResistance 918 2472 1555
puc19 1 531 531
puc19 2563 2668 106
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Fowler, B. “DICER1 deficit induces Alu RNA toxicity in age-related macular 
degeneration”, University of Kentucky Endowment Program (‘Brains for Bucks’), 
Boone Center, Lexington, KY, March 30, 2011.  
 
 
Journal club presentations 
 
“K⁺ efflux is the common trigger of NLRP3 inflammasome activation by bacterial 
toxins and particulate matter” Paper Reviewed: Muñoz-Planillo et al., Immunity, 
2013. J. Ambati Lab journal club, December 1, 2013.  
 
“DICER- and AGO3-dependent generation of retinoic acid-induced DR2 Alu RNAs 
regulates human stem cell proliferation” Paper Reviewed: Hu et al., Nat Struct 
Mol Biol., 2012. J. Ambati Lab journal club, November 7, 2012.  
 
“Somatic retrotransposition: Holy moly!” Paper reviewed: Baille et al., Nature, 2011. 
J. Ambati Lab journal club. February 20, 2012.  
 
“Advances in synthetic mRNAs: Gene therapy and stem cells”. Papers reviewed: 
Kormann, M.S.D. et al., Nature Biotechnology, 2011; Warren L. et al., Cell, 2010. 
J. Ambati Lab journal club. February 13, 2011.  
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Travel grants 
 
Trans YTF Grant, FEBS workshop: Molecular and Cellular Mechanisms in 
Angiogenesis, October 14-17, 2012, Capri, Italy.  
 
National Eye Institute Travel Grant, ARVO Annual Meeting, May 6-10, 2012, Ft. 
Lauderdale, FL 
 
 
Research Fellowships 
 
Doris Duke Charitable Foundation, WBS #3048105306, Grant title “Short non-
interfering RNAs as novel therapies for age-related macular degeneration” (2012-
2013) 
National Institutes of Health, T32 Fellowship (T32HL091812) (2011-2012)  
National Institutes of Health, National Center for Research Resources and the 
 National Center for Advancing Translational Sciences (UL1RR033173) (2011-
2012)   
 
University of Kentucky; Advisor: Jayakrishna Ambati 
Medical Student Summer Research Fellowship (Summer 2010) 
Physician Scientist Mentored Research Fellowship (February 2011-2012) 
 
Professional memberships 
 
2009- 2014  Member, The Association for Research in Vision and Ophthalmology 
2012   Member, American Society for Biochemistry and Molecular Biology  
2012-Present  Ad-Hoc Journal Reviewer, Investigative Ophthalmology & Visual Science 
 
